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ABSTRACT OF THE DISSERTATION 
Molecular Mechanisms That Govern Human Cardiac Stem Cell Age Disparity 
by 
Tania Fuentes 
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics 
Loma Linda University, June 2015 
Dr. Mary Kearns-Jonker, Chairperson 
 
Transplantation of adult endogenous cardiovascular progenitor cells for heart 
repair results in some clinical benefit, however these stem cells lack the regenerative 
capacity unique to neonatal cardiovascular stem cells. The goal of this work was to 
identify mechanisms that contribute to the decline of cardiac stem cell regenerative 
ability with age and investigate novel therapeutic strategies to improve cardiac stem cell 
function.  When comparing neonatal and adult cardiovascular stem cell clones, both cell 
types were capable of cardiomyogenic differentiation.  However, the expression levels of 
forty-one microRNAs were significantly altered with age.   Expression differences were 
correlated with reduced proliferation and a limited capacity to invade in response to 
growth factor stimulation in adult progenitors.  This information can be utilized to 
develop novel therapeutics and improve outcomes after stem cell-based treatment for 
heart failure. 
  
1 
CHAPTER ONE 
INTRODUCTION 
 
The ability of stem cells to stimulate repair of the heart, an organ once thought to 
be static and unable to regenerate, has the potential to transform modern medicine.  Each 
year, an estimated 620,000 Americans have a new coronary attack and 295,000 have a 
recurrent attack (Go et al., 2014).  On average it takes over an hour for a patient to 
receive medical attention (Fosbøl et al., 2013; Rasmussen et al., 2014), and once a patient 
is treated, there is significant heart muscle damage.  Various types of stem cells capable 
of cardiac differentiation have been advanced to human clinical trials in an effort to repair 
the injured heart (R. Bolli et al., 2011; Delewi et al., 2014; Karantalis et al., 2014). 
 
Bone Marrow Mononuclear Cells 
More than 50 clinical trials using bone marrow mononuclear cells (BMMCs) as a 
cell-based therapy for the infarcted heart have been completed (Delewi et al., 2014).  
Unfractionated BMMCs are a heterogeneous mixture of cell types containing monocytes, 
lymphocytes, haematopoietic progenitor and precursor cells and an occasional 
haematopoietic stem cell.  Thus far, the transplantation of unfractionated bone marrow 
mononuclear cells for heart injury has an excellent safety profile (Xu, Ding, Zhao, Pu, & 
He, 2014).  The functional outcomes after transplantation, however, tend to be wide-
ranging.  Some have attributed heterogeneity in functional outcomes to differences in 
protocols for BMMC harvest, isolation, storage, and delivery (Wollert, 2015).  Others 
have attributed the inconsistency of functional outcome to data integrity (Nowbar et al., 
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2014).  An analysis of 49 clinical trials, including both fully randomized and not fully 
randomized trials, revealed that there is a positive correlation in number of discrepancies 
in published work and the reported percentage improvement in LVEF (Nowbar et al., 
2014).  Meta-analyses that only include fully randomized clinical trials have determined 
that the benefit in left ventricular ejection fraction after BMMC transplantation either for 
myocardial infarction or chronic heart failure falls somewhere between 2.55 – 3.54% 
(Delewi et al., 2014; Xu et al., 2014).  This modest benefit, although promising is not 
sufficient to completely ameliorate loss of function after heart injury. 
 
Induced Pluripotent Stem Cells 
Induced pluripotent stem cells (iPSCs) have not yet advanced to clinical trials but 
are a cell type that is capable of cardiomyogenic differentiation and holds promise for 
regenerating the heart.  Induced pluripotent stem cells originate as differentiated cells 
that, through the introduction of defined factors, gain a state of pluripotency functionally 
similar to embryonic stem cells.  iPSC can be generated through viral-mediated 
overexpression of proteins (Giorgetti et al., 2009; Haase et al., 2009; Martinez-Fernandez 
et al., 2009; Takahashi & Yamanaka, 2006) or small RNAs (Anokye-Danso et al., 2011; 
S.-L. Lin et al., 2008; Miyoshi et al., 2011).  However, due to cancer concerns, non-viral 
methods such as exposure to protein extracts (Park et al., 2014) or defined chemicals 
(Hou et al., 2013) have also been developed to reprogram cells.   
 
iPSC-derived Cardiac Progenitors 
Induced pluripotent stem cells can be utilized to form cardiovascular progenitors 
3 
by partially differentiating iPSCs into cardiomyocytes, these cardiovascular progenitors 
can be stably maintained in culture once differentiation-inducing signals are eliminated 
(Cao et al., 2013).  iPSC-derived multipotent cardiovascular progenitors have the ability 
to form all three cardiovascular lineages (Carpenter et al., 2011; B. Lin et al., 2012; Lu et 
al., 2013; Alessandra Moretti et al., 2010; Nsair et al., 2012), and once differentiated, 
cardiomyocytes derived from iPSC multipotent cardiac progenitors can form electrically 
and mechanically coupled large-scale 2D cell cultures with mature electrophysiological 
properties (Christoforou et al., 2013). Human iPSC-derived multipotent cardiovascular 
progenitors, when seeded into a decellularized heart, migrate, proliferate, and 
differentiate into cardiovascular lineages.  After 20 days, seeded hearts exhibited 
spontaneous contractions and generated mechanical force (Lu et al., 2013).  In vivo, when 
transplanted into the rat myocardium, human iPSC-derived multipotent cardiac 
progenitors were retained long term (10 weeks) with evidence of differentiation into cells 
of cardiac lineage (Carpenter et al., 2011).   
Not all partially differentiated pluripotent cells, have an equal propensity for 
cardiac lineage differentiation.  In mice, sorting for the cell surface marker combination 
of VEGFR1 and VEGFR3 can enrich for an iPSC-derived Isl1+/Nkx2.5+ cardiac 
progenitors with trilineage cardiovascular potential in vitro.  Twenty-eight days post-
transplantation in vivo, there was evidence of cardiovascular progenitor cell engraftment 
and differentiation into mature cardiomyocytes in vivo (Nsair et al., 2012).   Similarly, 
expression of VEGFR2 (KDR) in mouse iPSC-derived cardiac progenitors can separate 
multipotent progenitor functional ability.  Transplantation of KDR+ cells results in 
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superior functional benefits and a greater number of vascular structures when compared 
with KDR– cells (Mauritz et al., 2011). 
 
Human iPSC in Large Animal Models 
To date, the majority of studies completed in large animal models with iPSCs 
have utilized transplantation of human iPSCs once the cells have been successfully 
differentiated into relevant cardiovascular lineages.   
Transplantation of cardiomyocyte cell sheets derived from human iPSC after 
ischemic cardiomyopathy significantly improved cardiac performance and attenuated left 
ventricular remodeling with no teratoma formation in pigs (Kawamura et al., 2012).  
After 8 weeks, however, few cells survived within the myocardium.  Improved cell 
survival can be achieved with transplantation of highly vascularized omentum flap tissue 
along with iPSC-derived cardiomyocyte sheets (Kawamura et al., 2013).  Transplantation 
of human iPSC-derived endothelial cells and smooth muscle cells into swine following 
ischemia-reperfusion injury can improve c-kit+ cell recruitment, vascular density, and 
ATP turnover rate after 4 weeks.  This treatment also improves blood flow and 
contractile function in the border zone (Xiong et al., 2013).   Combination of iPSC-
derived cardiomyocytes, endothelial cells, and smooth muscle cells, when administered 
in pigs with a fibrin patch containing IGF-1 significantly improves left ventricular 
function, decreases infarct size, and reduces apoptosis after myocardial infarction (L. Ye 
et al., 2014).  
 
Considerations for iPSC Clinical Use 
In spite of promising results after application of iPSC (both differentiated and 
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undifferentiated) as a cell-based therapy for cardiac injury in large animals, there are 
several roadblocks that must be overcome before iPSC transplantation can feasibly be 
considered for use in a clinical setting. The whole process of reprogramming tends to be 
mutagenic resulting in chromosomal alterations and a significant number of copy number 
variants (Gore et al., 2011; Hussein et al., 2011; Ji et al., 2012; Park et al., 2014).  
Furthermore, induced pluripotent stem cells, although genetically reprogrammed, retain 
an epigenetic memory (including unique DNA methylation patterns) of their cell type of 
origin (Ohi et al., 2011).   This epigenetic memory can result in an inherent predisposition 
towards differentiation into a given cell type (Rizzi et al., 2012).  Therefore, induced 
pluripotent stem cells derived from easily accessible tissues such as the skin, may not be 
as ideal for cardiac transplantation as other cell types which are closer to the cardiac 
lineage.  Optimization of reprogramming and differentiation methods is necessary to 
ensure that the iPSCs and iPSCs-derived cells fully mimic the desired cell type  
Although induced pluripotent stem cells are an innovative and readily accessible 
source of cardiovascular progenitors, the possibility of cancerous transformation and low 
efficiency of reprogramming with non-viral methods present a significant barrier to their 
use in clinical practice. 
 
Human Endogenous Cardiac Stem Cells 
Of the cell types investigated for their ability to regenerate the heart after injury, 
resident cardiac progenitor cells (CPCs) are a preferred cell type because of their high 
propensity for cardiomyogenic differentiation, relative safety, and lack of cancerous 
transformation when transplanted in vivo (Konstantinos Malliaras et al., 2014b).  When 
compared with stem cells that reside outside of the heart such as bone marrow-derived 
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mesenchymal stem cells, adipose-tissue-derived mesenchymal stem cells, or bone 
marrow mononuclear cells, resident cardiac progenitors have a higher capacity for 
cardiomyogenic differentiation and paracrine signaling resulting in greater improvements 
in cardiac function after transplantation in vivo (Koninckx et al., 2011; Li et al., 2012; 
Takehara et al., 2008).  In human clinical trials, utilization of resident cardiac stem cells 
as a cell-based treatment after myocardial infarction have shown that these cells can 
reduce infarct size and result in improvements in patient outcomes lasting at least 1-2 
years (R. Bolli et al., 2011; Makkar et al., 2012; Konstantinos Malliaras et al., 2014b).   
Several stem cell types have been isolated from the heart and defined on the basis 
of surface phenotype including ckit+ cells, cardiospheres, cardiosphere-derived cells, and 
ISL1+ cells (Table 1).  Which of these cells types is most optimal for cardiovascular 
regeneration is unknown.  In this chapter we will summarize the current literature on 
heart-derived cardiac stem cells.  
 
Ckit+ Cardiac Stem Cells 
Ckit+ cardiac stem cells (CSCs) are isolated from the heart by enzymatic 
digestion and sorted on the basis of tyrosine protein kinase, ckit, expression and absence 
of leukocyte common antigen, CD45.  Ckit antigen expression can be found in a variety 
of tissues within the body (Lammie et al., 1994).  Ckit+ cells isolated from the heart have 
the ability to form all three cardiac lineages (Claudia Bearzi et al., 2007).  According to 
Bearzi et al. (2007), these cells typically do not express CD34, CD31 (platelet/endothelial 
cell adhesion molecule), or KDR (kinase insert domain receptor) and a small percentage 
(0.5%) of ckit+ cardiac stem cells express GATA4 (gata binding protein 4) and Nkx2.5  
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Table 1.    Markers that define human heart-derived stem cells* 
Ckit+ Cardiac Stem Cells 
(Bearzi et al., 2007)     
 
Negative for: CD45, CD34, CD31, KDR 
Positive for: Ckit 
└ Vascular Ckit+ Stem Cells 
        (Bearzi et al., 2009) 
Negative for: CD45, CD34, CD133, αSA 
Positive for: Ckit, KDR, CD31low, TGF-β1low 
 
└ Myogenic Ckit+ Stem Cells 
        (Bearzi et al., 2009) 
Negative for: CD45, CD34, CD133, CD31, TGF-
β1, KDR 
Positive for: Ckit, αSAlow 
 
└ Endothelial Ckit+ Stem Cells 
         (Sandstedt et al., 2010) 
Negative for: CD45 
Positive For: Ckit, KDR, CD31, CD34, CXCR4 
 
└ Ckit+ cardiac stem cells 
         (Koninckx et al., 2011)  
Negative for: CD140, CD34, CD133, CD45, FGF 
Positive for: CD13, CD29, CD44, CD73, CD90, 
EGFR (lost Ckit expression with passaging) 
 
└ Lin Depleted Ckit+ CSCs 
         (He et al., 2011) 
Negative for: CD45, CD34, CD133, CD31, KDR 
Positive for: Ckit 
 
└ non-Lin depleted Ckit+ CSCs  
         (He et al., 2011) 
Negative for: CD45, CD34, CD133 
Positive for: Ckit, KDR, CD31 
 
Cardiospheres 
(Davis et al., 2009) 
Negative for: CD45, CD34 
Positive for: Core (Ckit, Nkx2.5, connexin 43, 
Desmin)   Periphery (CD31, CD105, αMHC, cTnI, 
CD133, MDR-1, CD90) 
 
Cardiosphere-derived Cells  
(Li et al., 2012) 
Negative for: CD45, CD34, CD31, CD133 
Positive for: Ckitlow, CD105, CD29, CD90low 
 
ISL1+ Cardiac Progenitors 
(Serradilfalco et al., 2011) 
 
Positive for: ISL1, Ckit (only identified in fetus) 
 
└ Ckit+ ISL1+ CPCs  
  (T. Fuentes et al., 2013) 
Negative for: HLADr 
Positive for: ISL1, Ckit, CD73, CD105, CD44, 
CD13, IGF1R, CXCR4, CXCR7, HLA class I, 
CD140a 
 
└ hESC-derived ISL1+ CSCs 
      (A. Moretti et al., 2006) 
Negative for: Tbx5 
Positive for: ISL1, KDR, Nkx2.5, Gata-4, Tbx20, 
Tbx1 
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└ hESC-derived ISL1+ CSCs 
     (Bu et al., 2009) 
Negative for: KDR, Nkx2.5 
Positive for:  ISL1 
 
└ hESC-derived ISL1+ CSCs 
     (K. O. Lui et al., 2013) 
Negative for: Neurofilament 
Positive for: ISL1, VEGFR1, KDRlow 
 
*Modified from (Tania Fuentes & Kearns-Jonker, 2013)  
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(cardiac-specific homeo box) (Claudia Bearzi et al., 2007).  Sandstedt et al. (2014) using 
single cell PCR analysis found that 81% of these cell express vWF, 72% express KDR, 
and 1.1% express Nkx2.5 and suggested that instead of being truly multipotent, this 
population consists of some already lineage committed progenitors, more specifically 
endothelial progenitors (Sandstedt et al., 2014; Sandstedt, Jonsson, Lindahl, Jeppsson, & 
Asp, 2010).  
The role of ckit+ cardiovascular progenitors in myocardial regeneration is highly 
debated (Molkentin, 2014; Nadal-Ginard, Ellison, & Torella, 2014a, 2014b; Torella, 
Ellison, & Nadal-Ginard, 2014; van Berlo et al., 2014).  Ellison et al found that ablation 
of endogenous cardiac stem cells abolishes regeneration after myocardial damage.  
Recovery of myocardial regeneration can be achieved by exogenous administration of the 
progeny of one ckit+ cardiac stem cell (Ellison et al., 2013).  After regeneration, selective 
suicide of transplanted cells and their progeny abolishes regeneration, severely impairing 
ventricular performance (Ellison et al., 2013).   This suggests that the ckit+ cardiac stem 
cell is mainly responsible for the regenerative capacity of the heart.   
Critics of this idea include van Berlo et al (2014) who, using a genetic lineage 
tracing, reported that endogenous c-kit+ cells produce new cardiomyocytes within the 
heart but at a very low percentage of approximately 0.03 or less which may be 
functionally insignificant to myocardial regeneration. Consistent with this, Senyo et al 
found, using pulse-chase and genetic fate mapping, that the genesis of cardiomyocytes 
with age occurs mainly through the division of pre-existing cardiomyocytes, and that this 
process increases after myocardial injury (Senyo et al., 2013).  Whether or not ckit+ cells 
contribute significantly to the cardiomyocytes within the heart after injury, although 
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highly debated, may not be as important as their paracrine role in regeneration.  A recent 
study by Hong et al found that despite rapid disappearance of ckit+ cardiac stem cells 
following transplantation, intracoronary delivery of stem cells significantly improved left 
ventricular function at 35 days post-transplant.  Therefore, functional improvement may 
be not be dependent on survival and differentiation of transplanted cells (Hong et al., 
2014).   
Because of the inherent heterogeneity of stem cells sorted on the basis of ckit and 
absence of CD45 expression, subpopulations of ckit+ cardiovascular progenitors have 
differing functional properties.  Ckit+ cardiovascular progenitors that also express KDR 
tend to be found in epicardial coronary arteries, arterioles, and capillaries and are 
vascular progenitors whereas KDR- Ckit+ cardiovascular stem cells are found in the 
myocardial interstitium and are myogenic progenitors (C. Bearzi et al., 2009).  Insulin-
like growth factor-1 receptor expression can also separate functionally distinct ckit+ 
progenitors.  Transplanted IGF1R+ ckit+ cardiac stem cells can significantly increase 
infarcted tissue regeneration (12mm) when compared with IGF1R- cardiac stem cells 
(7mm).  Pretreatment of these cells with IGF-2 can further improve tissue regeneration 
(15mm) and ejection fraction (D'Amario et al., 2011).  Cardiac stem cells (because they 
use asymmetric chromatid segregation when dividing) can also be subdivided by the 
integrity of their DNA.  Kajstura et al found that transplantation of cells that retained the 
template DNA when compared with ckit+ cardiac stem cells with the synthesized copy of 
DNA resulted in a greater restoration of infarct thickness (60mm3 vs 25mm3) and a 
greater attenuation of diastolic wall stress (Kajstura et al., 2012). 
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The percentage and functional properties of ckit+ cardiac stem cells within the 
heart is not consistent from person to person (Gambini et al., 2012; Song et al., 2013).  
Females have a greater number of ckit+ cardiac progenitors in their heart than males 
(Itzhaki-Alfia et al., 2009) and failing hearts can have as many as 4 times the number of 
ckit+ cardiac progenitors (Kubo et al., 2008).  Aging can also play a role in stem cell 
distribution and function.  The total number of ckit+ cardiac stem cells in the heart 
decreases dramatically after the first month of life (Mishra et al., 2011).  Even well into 
adulthood, age remains a factor in the yield of ckit+ cardiac stem cells that can be 
obtained from a tissue biopsy (Aghila Rani, Jayakumar, Sarma, & Kartha, 2009).  With 
age, the percentage of senescent ckit+ stem cells in the heart increases, as demonstrated 
by telomere shortening, attenuated telomerase activity, telomere dysfunction- induced 
foci, and the expression of cyclin-dependent kinase inhibitor 1A and 2A (Cesselli et al., 
2011).  In young stem cells, pretreatment with Ephrin A1 prior to transplantation resulted 
in enhanced speed of CSC migration,  a 37% decrease in infarct size (2 fold greater than 
CSC alone), and a significant increase in ejection fraction and left ventricular developed 
pressure (Goichberg et al., 2011).  In aged stem cells, on the other hand, elevated levels 
of reactive oxygen species interfered with receptor auto-phosphorylation and downstream 
signaling resulting in inhibition of migratory ability in vitro and impaired translocation in 
vivo in the damaged heart. Overexpression of functionally intact Ephrin type-A receptor 2 
in old CPCs corrected the defects in signaling and enhanced cell motility (Goichberg et 
al., 2013).  
In spite of evidence to the contrary, the old heart is not devoid of functional 
cardiac stem cells, both senescent CSCs with extremely short telomeres and 
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phenotypically young CSCs carrying long, intact telomeres co-exist within the aged 
heart. The CSCs with long telomeres, however, are quiescent and do not re-enter the cell 
cycle or form differentiated progeny (Sanada et al., 2014).  Therefore strategies to isolate 
or activate these phenotypically young stem cells within the aged heart are necessary to 
enhance regeneration. 
 
Ckit+ Cardiac Stem Cells in Large Animals 
Few studies have utilized ckit+ cardiac stem cells in large animal models.  Bolli et 
al delivered ckit+ cardiac stem cells into the infarct-related artery three months after 
ischemia-reperfusion injury in pigs (n=11).  This resulted in significantly greater ejection 
fraction (51.7±2.0% versus 42.9±2.3%, P<0.01 by echo) when compared with controls 
(n=10) at one month post infusion.  Green fluorescent protein-labeling of CSCs allowed 
for identification of CSC differentiation into cells that expressed cardiac troponin I, 
troponin T, myosin heavy chain, and connexin 43.  There was also evidence of labeled-
CSCs forming vascular structures that expressed alpha-smooth muscle actin (R. Bolli et 
al., 2013). 
Welt et al injected 1.6 million ckit+ CSCs 6 weeks after coronary ligation in the 
canine heart, and measured long-term changes in outcomes after 30 weeks. In the cell-
treated group (n=13), the ejection fraction remained stable from 6 weeks to 24 weeks 
post-infarct (30.5% to 32.9%) when compared with the control group (n=6) which 
declined during the same time frame (35.2% to 26.4%).  This suggest that the favorable 
outcomes after cell therapy can potentially last long-term (Welt et al., 2013). 
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A combination treatment of CSCs along with mesenchymal stem cells (MSCs) 
results in additive improvements in heart regeneration.  Human cardiac stem cells at a 
dose of 1 million cells and MSCs at a dose of 200 million cells were administered 14 
days after myocardial infarction in Yorkshire swine.  After 4 weeks, there was a 2-fold 
greater reduction in infarct size (21.1% combo, n=5 vs 10.4% ckit+ CSCs alone, n=5 and 
9.9% MSCs alone, n=5) and a 7-fold enhanced engraftment in the combination cell 
therapy group when compared to either cell therapy alone.  In all cell treated groups, 
ejection fraction was restored to baseline whereas in control (n=5) it remained 
persistently depressed (Williams et al., 2013). 
 
Cardiospheres and Cardiosphere-derived Cells 
Cardiospheres are exclusively heart-derived stem cells (White et al., 2013) that 
are treated with specific growth medium to form non-adherent sphere-like structures 
(Smith et al., 2007).  The core of cells within the cardiosphere contains cells that express 
ckit, nkx2.5, and desmin (Davis et al., 2009).  Cardiospheres also have a percentage of 
cells that are CD45+, these cells do not play a role in cardiosphere formation and their 
function in regeneration is unclear (J. Ye et al., 2013).  Cardiospheres when plated and 
grown as a monolayer are called cardiosphere-derived cells (CDCs).  When compared 
with other cell types such as bone marrow-derived mesenchymal stem cells, adipose 
tissue-derived mesenchymal stem cells, and bone marrow-derived mononuclear cells, 
CDCs have superior angiogenic potential and secrete higher levels of angiogenic and 
antiapoptotic factors.  In vivo transplantation of CDCs, when compared with these other 
cell types, results in the highest improvements of cardiac function and highest levels of 
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cell engraftment after myocardial infarction (Li et al., 2012).  The mechanism for the 
regeneration of viable myocardium after CDCs transplantation is mediated mainly 
through upregulation of host cardiomyocyte cycling and recruitment of endogenous 
progenitors (K. Malliaras et al., 2013).  
Cardiosphere-derived cells retain their ability to form sphere-like structures 
(secondary cardiosphers) when exposed to epidermal growth factor (Chimenti et al., 
2010).  Exposure of CDCs to epidermal growth factor can also significantly improve 
functional parameters such as migration, proliferation, and wound healing of CDCs 
(Aghila Rani & Kartha, 2010).  Secondary sphere formation can enhance the 
functionality of cardiosphere-derived cells.  The 3-D formation of the cardiospheres when 
compared with the monolayer of cardiosphere derived cells has higher levels of Troponin 
I (Machida, Takagaki, Matsuoka, & Kawaguchi, 2011).  When transplanted into the 
infarcted myocardium, secondary cardiospheres result in higher levels of engraftment, 
greater improvements in left ventricular dysfunction and reduced infarct size when 
compared with transplantation of CDCs alone (Cho et al., 2012).   
Cardiospheres have the unique advantage of diverse cell types within a natural 3-
D formation which mimics the stem cell niche.  This periphery of supporting cell 
populations have a paracrine role that enhances regeneration (Davis et al., 2009).  In spite 
of the superior regenerative effects after cardiosphere transplantation when compared 
with CDCs, their relatively large size is a disadvantage and presents safety concerns.  
Cardiospheres exert a dose-dependent functional benefit, with higher doses resulting in 
greater benefits (Shen, Cheng, & Marban, 2012), however transplantation of large 
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numbers of cardiospheres via intracoronary infusion may result in adverse events such as 
microembolism therefore cardiosphere-derived cells are more widely used. 
The majority of the benefit after CDC transplantation is mediated through 
secreted factors and cell-to-cell signaling.  Direct differentiation of CDCs after 
transplantation only accounts for 20-50% of increases in myocardial viability and 
capillary density (Chimenti et al., 2010).  This was measured by injecting human cells 
into SCID mice and measuring the origin of regenerated tissues.  Only 9.6% of the total 
capillaries were found to be of human origin which amounts to approximately 20% of 
enhanced angiogenesis, and only 11.8% of myosin heavy chain expressing cells in the 
myocardium were of human origin accounting for half of the 20% increase in relative 
tissue viability (Chimenti et al., 2010).   
Transplantation of both syngeneic and allogeneic CDCs significantly improves 
infarct size, infarcted wall thickness, and ejection fraction after transplantation, compared 
to controls even though the number of retained cells significantly drops at 3 weeks (K. 
Malliaras et al., 2012).  This suggests that paracrine secretions rather than direct 
differentiation are mainly responsible for functional improvement as cells do not engraft 
long-term.  When transplanted in vivo, CDCs secrete VEGF, HGF, and IGF1, and in vitro 
CDC-conditioned media exerts an antiapoptotic effect on neonatal rat ventricular 
myocytes, a proangiogenic effect on human umbilical vein endothelial cells, and can 
reverse angiotensin II-mediated contractile dysfunction in adult cardiomyocytes 
(Chimenti et al., 2010; Maxeiner et al., 2010).  The paracrine activity of CDCs is 
regulated by the ERK pathway.  In ERK stimulating conditions growth factors such as 
VEGF have increased secretion, whereas in ERK inhibitory conditions cells are more 
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prone to cardiomyogenic differentiation (H. J. Lee, Cho, Kwon, Park, & Kim, 2013).  
CDCs also secrete exosomes which play a large role in their regenerative ability.  
Exosomes isolated from CDC conditioned medium inhibits cardiomyocyte apoptosis, 
promotes cardiomyocyte proliferation, and enhances angiogenesis of endothelial cells. 
Injection of exosomes into the heart of injured mice can recapitulate the benefit of CDC 
transplantation (Ibrahim, Cheng, & Marban, 2014).   
Paracrine secretions can also influence the plasticity of surrounding cell types.  
Mesenchymal stem cells derived from the mediastinal fat when exposed to cardiosphere 
conditioned medium partially differentiate towards the cardiac lineage (Siciliano et al., 
2015).  Although the benefit of CDC transplantation is mainly paracrine mediated, in 
vivo, transplantation of CDC conditioned media alone does not result in equal 
improvements in left ventricular ejection fraction and number of cycling cardiomyocytes 
when compared with transplantation of CDCs.  In vitro, direct cell to cell contact results 
in the greatest enhancement of cardiomyocyte proliferation compared with CDCs grown 
in a transwell contact-free system (Xie et al., 2014).   
Although the heterogeneity of cell types within cardiosphere-derived cells 
contribute to their therapeutic efficacy, some cell types are not required for their benefits.  
A cell type commonly within the CDC population is the CD90 population.  CD90 
expression usually identifies a mesenchymal/myofibroblast cell.  This cell type when 
isolated from cardiospheres displayed a reduced cardiac differentiation potential when 
compared with CD90- cells (Gago-Lopez et al., 2014).  In vivo, depletion of cells that 
express CD90 prior to transplantation in a mouse model of myocardial infarction 
augments the functional potency of CDCs resulting in a ~7% increase in LVEF above 
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transplantation of CDCs alone (Cheng, Ibrahim, et al., 2014). Most interestingly, 
depletion of another common cell type within CDCs, the ckit+ cardiac stem cell, does not 
compromise the structural and functional benefits of CDCs in a mouse model of 
myocardial infarction. In the CADUCEUS clinical trial, there was no correlation between 
percentage of ckit+ cells and the benefit of CDC transplantation in humans (Cheng, 
Ibrahim, et al., 2014).  Therefore, the cell type responsible for the therapeutic benefits 
after CDC transplantation are distinct from ckit+ cardiac stem cells. 
With disease, the characteristics of cardiosphere-derived cells changes.  Some of 
these alterations can negatively influence CDC function, CDCs cultured from diabetic 
patients had 1.6-fold more CD90+ cells than those from non-diabetic patients (Chan et 
al., 2012).  Other disease-induced modifications can surprisingly improve CDC function.  
CDCs from end-stage heart failure patients demonstrated a significantly higher 
restoration of ventricular function, prevented adverse remodeling, and enhanced 
angiogenesis after transplantation in an infarcted rodent model when compared to control 
heart disease patients (Cheng, Malliaras, et al., 2014; Sharma et al., 2015).  These 
positive changes were found to be due to an enhanced secretome activity of end stage 
heart failure-derived CDCs.  
Cardiospheres and Cardiosphere-derived Cells in Large Animals 
There have been several studies that have utilized large animal models to study 
the therapeutic efficacy of cardiosphere-derived cell transplantation.  Some have used 
human cells in large animals.  In a cyclosporine A immunosuppressed pig, Takehara et al 
(2008) transplanted human CDCs or bone marrow-derived mesenchymal stem cells with 
basic fibroblast growth factor in a slow release hydrogel after myocardial infarction.  
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Four weeks after transplantation, mesenchymal stem cells with bFGF (n=6) did not 
significantly increase LVEF above bFGF alone (n=8).  Whereas, transplantation of CDCs 
with bFGF (n=9) resulted in an additive effect over bFGF alone and significantly 
increased LVEF (38.4% vs 30.1% baseline) and regional wall motion (58.5% vs 46.2% 
baseline) which was significantly evident when compared with the change in cardiac 
function in the control group (n=6).  In pigs that received CDCs, thirty-three percent of 
cardiomyocytes generated from the transplanted cells were the result of direct 
differentiation rather than cell fusion as confirmed by immunohistochemical 
colocalization of the human Y chromosome with sarcomeric alpha actin.   In pigs that 
received mesenchymal stem cells only 10% of cardiomyocytes were the result of direct 
differentiation (Takehara et al., 2008).  
Others have employed pig cardiosphere-derived cells delivered either 
syngeneically or allogeneically.  Cardiosphere derived cells have a diameter of 21μm 
which when compared with the 7-10µm capillary luminal diameter is relatively large.  
Therefore infusion of high numbers can result in microvascular occlusion and infarct 
(Johnston et al., 2009).  Regeneration of tissue without microvascular infarction can be 
achieved with transplantation of  ≥107  CDCs (300,000/kg) but less than 2.5 x 107 CDCs. 
Unfortunately, due to low levels of engraftment, transplantation of 107 CDCs by over-
the-wire balloon catheter (n=7) did not significantly improve left ventricular mass, infarct 
size, end-diastolic volume, end-systolic volume, left ventricular ejection fraction or end-
diastolic pressure.  However, cardiac magnetic resonance revealed that CDC treatment 
did decrease relative infarct size (19.2% to 14.2% of left ventricle infarcted, P=0.01), 
whereas placebo did not (17.7% to 15.3%, P=0.22) after 8 weeks (Johnston et al., 2009).   
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To improve engraftment an open-chest surgery with twenty intramyocardial 
injections of either cardiospheres or cardiosphere-derived cells was used in pigs four 
weeks post myocardial infarction (S. T. Lee et al., 2011).  After 24 hours engraftment 
regardless of dose (0.5 million, 2 million, or 10 million) was 8-9% in remote normal 
myocardium.  In the peri-infarct zone, however, engraftment was inversely related to the 
number of injected cells with the lowest dose of cell (0.5million) resulting in the highest 
percentages of engraftment.  By ventriculography, both cell-treated groups (cardiospheres 
n=8, CDCs n=10) had a significant increase in LVEF when compared with the placebo 
group (n=11, p<0.01).  In 2 animals lacZ labeling was used to trace cell fate, after 8 
weeks, the expression of lacZ was confirmed in cardiomyocytes, however whether these 
are due to direct differentiation or cell fusion is unknown.  Cardiosphere and 
cardiosphere-derived cells had very similar outcomes with cardiosphere transplantation 
resulting in superior improvements in end-systolic elastance, delta end-diastolic pressure, 
and apical septal thickening (S. T. Lee et al., 2011).   
Allogeneic transplantation of mismatched CDCs by intracoronary infusion in a 
porcine model 2-3 weeks after myocardial infarction revealed that in large animals 
allogeneic transplantation (n=5) can attenuate remodeling, improve global and regional 
function, decreased scar size, and increase viable myocardium when compared with 
vehicle (n=5) 2 months post-treatment (Konstantinos Malliaras et al., 2013).  Left 
ventricular ejection fraction was preserved in cell-treated (∆ -0.5, p=0.73) when 
compared with control animals (∆ -9.9, p<0.001).  By MRI, scar size was unchanged in 
controls (∆ 0.4%, p=0.33) but decreased in CDC-treated animals (∆ -3.6%, p=0.026).  
There was also a significant increase in viable myocardial mass in CDC-treated animals 
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(∆ 10.7 g) when compared with controls (∆ 2.7 g, p=0.003) after 2 months.  Although 
allogeneic transplantation results in mild local mononuclear infiltration, there is no 
systemic immunogenicity associated with mismatched CDC transplantation.  Cardiac 
retention after 24 hours was only 4.3% using luciferase labeled CDCs.  At 2 weeks post 
infusion cells could still be detected within the recipient myocardium, however by 2 
months, no allogeneic cells were detected (Konstantinos Malliaras et al., 2013). 
CDCs also have beneficial effects when administered very early after myocardial 
infarction.  When applied this early, they can be used as therapy to prevent 
cardiomyocyte death as opposed to a therapy to regenerate lost tissue.  Kanazawa et al 
(2015) conducted a short-term (48 hours) study of CDC administration 30 minutes after 
reperfusion to investigate relative safety as an adjunctive therapy to reperfusion in 
porcine model of myocardial infarction.  Comparison of doses revealed that higher doses 
of allogeneic CDCs (7.5 or 10 million cells, n=5 each) rather than low dose (5 million 
cells, n=5) resulted in cardioprotection.  Transplantation of ~8.7 million cells (n=4) 
resulted in significant decreases in TUNEL positive cardiomyocytes within the border 
zone after 48 hours. There was also a significantly smaller infarct size in the CDC-treated 
group (59.7%) when compared with sham (81.0%, n=5) or placebo (80.3%, n=5) as well 
as a decrease in microvascular obstruction area when compared with controls (Kanazawa 
et al., 2015). 
 
Current Clinical Trials 
On the basis of the promising outcomes in large animal work, administration of 
endogenous cardiac stem cells as a therapy for cardiac injury has moved into human 
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clinical trials.  Currently there are four phase I, safety and efficacy, clinical trials 
completed.  
The clinical trial entitled, “Intracoronary cardiosphere-derived cells for heart 
regeneration after myocardial infarction” or CADUCEUS trial was led by Eduardo 
Marban.  This trial included 25 patients (17 cell-treated, 8 standard care) who received a 
dose of autologous CDCs.  Cell therapy, after 6 months, resulted in reductions in scar 
mass (p=0.001), increases in viable heart mass (p=0.01) and regional contractility 
(p=0.02), and regional systolic wall thickening (p=0.015) by MRI. At this time point, 
changes in end-diastolic volume, end-systolic volume, and LVEF did not differ between 
groups (Makkar et al., 2012).  At 12 months, transplantation of CDCs resulted in a 
significant reduction in scar mass (11.9g decrease) and significant increase in viable mass 
(22.6g increase).  There was also improved regional contractility and regional systolic 
wall thickening.   However, at 12 months, functional measurements of end-diastolic 
volume, end-systolic volume, and LVEF did not differ significantly between groups 
(Konstantinos Malliaras et al., 2014a).  At 12 months the only serious adverse event 
determined by the data safety monitoring board to be possibly related to CDC therapy 
was a non-ST-segment elevation MI in 1 CDC-treated patient at 7 months after cell 
infusion. 
One of the largest clinical trials completed to date, using endogenous 
cardiovascular stem cells, is the “Administration of cardiac stem cells in patients with 
ischemic cardiomyopathy” or SCIPIO trial.  This trial led by Roberto Bolli, had a total of 
33 patients (20 cell-treated, 13 control) and tested the safety and efficacy of ckit+ cardiac 
stem cells (Roberto Bolli et al., 2012; Roberto Bolli et al., 2011).  Ckit+ stem cells were 
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isolated from the right atrial appendage, grown to sufficient numbers (maximum 106 
CSCs) and injected during coronary artery bypass grafting surgery 4 months after 
myocardial infarction.  After 2 years, there were significant improvements in left 
ventricular ejection fraction (41.7% at 2 years vs 29.7% at baseline).  This was 
accompanied by an increase in left ventricular viable mass (12.2% increase) and decrease 
in infarct size (15.7% decrease).  Other outcome measures such as the New York Heart 
Association classification and the Minnesota Living With Heart Failure Questionnaire 
score also improved significantly after 2 years.  No CSC-related adverse effects were 
reported. 
The clinical trial entitled, “Transcoronary Infusion of Cardiac Progenitor Cells in 
Patients With Single Ventricle Physiology” or TICAP is one of the only clinical trials in 
young patients with hypoplastic left heart syndrome and is led by Hidemasa Oh (Ishigami 
et al., 2014).  Fourteen patents (average age 1.8+/- 1.5 years) were enrolled in this study 
and received autologous CDCs ~30 days after staged procedures.  No serious adverse 
events were reported in the 18-month follow-up.  CDC-treated patients had increased 
cardiac function as measured by left ventricular ejection fraction at 3 months (52.1% vs 
46.9% at baseline) this increase persisted over the period of follow up (54.0% at 18 
months).  In contrast control patients had no significant increase in heart function at 3 
months (47.7% vs 46.7% at baseline) which was not significantly changed during the 
follow-up period (48.7% at 18 months).  
Cardiac stem cell transplantation, as evidenced by these three completed clinical 
trials, can result in improved patient outcomes, however full regeneration of the injured 
myocardium is likely to be achieved with a combination of cell types (Latham et al., 
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2013) and growth factors delivered in an engraftment-promoting medium (Mayfield et 
al., 2014).  Experiments in large animals and human clinical trials have highlighted the 
utility of administration of select growth factors (without cardiac stem cells) to ameliorate 
cardiac injury (Braitsch, Kanisicak, van Berlo, Molkentin, & Yutzey, 2013; Gao et al., 
2010; Henry et al., 2003; Hibbert et al., 2014; Jabbour et al., 2011; Koudstaal et al., 2014; 
Silverberg et al., 2001; Simons et al., 2002; Tritos & Danias, 2008).  A summary of 
results from human clinical trials with growth factors administered after cardiac injury 
can be found in table 2.   
The last of the completed clinical trials, which was completed by Hiroaki 
Matsubara in Japan, is the only clinical trial that uses both cardiac stem cells and bFGF-
infused biodegradable hydrogel.  This clinical trial is entitled, “Autologous Human 
Cardiac-Derived Stem Cell to Treat Ischemic Cardiomyopathy” or ALCADIA (Nakata et 
al., 2012) and uses stem cells from endomyocardial biopsisies, which express CD105, 
CD90, CD29, Nanog, Oct4, Gata4 and are negative for CD45.  These CSCs (5 x 105 
cells/kg) were delivered using 20 intramyocardial injections which were covered with a 
biodegradable gelatin hydrogel which contained 200µg of infused bFGF.  Six patients 
with ischemic cardiomyopathy were enrolled in this study.  This study has not yet 
published final results.  Preliminary data after 6 months indicate an improvement in 
LVEF in the cell-treated patients (from 26.7% to 35.8% by 3D Echo and 22.6% to 34.7%  
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by MRI), as well as a decrease in infarct volume/left ventricular mass (%) by MRI (from 
23% to 19.7%).  There was also a concomitant decrease in wall motion score (from 17.2 
to 6.6).  Maximum aerobic exercise capacity (VO2 peak) was increased by 4.5ml/kg/min.  
Of the 6 patients, one patient experienced an acute occlusion of a graft and was excluded 
from further evaluation and one experienced worsening heart failure during follow-up.  
No other adverse events were reported. Comparison with matched controls has not been 
reported. 
There are two clinical trials using endogenous cardiac stem cells that are currently 
enrolling participants.  The first is a phase I/II clinical trial led by Eduardo Marban and is 
the first trial to investigate the allogeneic use of endogenous cardiac stem cells in 
humans.  This trial is entitled, “Allogeneic Heart Stem Cells to Achieve Myocardial 
Regeneration” or ALLSTAR.   The primary endpoint is to test the safety of allogeneic 
cardiosphere-derived cell product.  This study expects an enrollment of 274 patients. 
Cells will be transplanted <3 months or 3-12 months after myocardial infarction to assess 
the ideal time frame for cell delivery.   At present, there are no released outcomes from 
this trial. 
The second is a phase II trial entitled PERSEUS and is a follow up trial on the 
phase I TICAP trial.  This trial uses cardiac progenitor cell infusion to treat univentricular 
heart disease.  This study has an estimated enrollment of 34 patients with hypoplastic left 
heart syndrome between the ages of 0 and 20 years of age.  The primary endpoint is to 
measure cardiac functional improvement after 3 months.  Cardiac function will also be 
measured after 12 months.  This study is currently enrolling patients and is expected to be 
completed in 2018. 
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Considerations for Transplantation of Endogenous CSCs 
There is growing evidence for the benefit of using allogeneic cardiac progenitors 
for cardiac transplantation (K. Malliaras et al., 2012; Tseliou et al., 2013).  However, it is 
unclear whether an immune response to these cells would negate their benefits when 
transplanted in humans.   The transplantation of allogeneic stem cells is likely to lead to 
T-cell mediated rejection by either indirect allorecognition, or through polymorphic 
variants of donor MHC being recognized by recipient T cells (Nehlin, Isa, & Barington, 
2011).  This T-cell mediated rejection is mediated by the expression of both MHC class I 
and co-stimulatory molecules including CD40, CD80, and CD86 (Nehlin et al., 2011).  
Without the presence of the co-stimulatory molecules, MHC class I binding to T cell 
receptors results in anergy, apoptosis of T cells, or tolerance-inducing immunoregulation 
(Nehlin et al., 2011).   
Results of experiments using ckit+ cells in vitro suggest they actually help reduce 
inflammation by activating T-regulatory cells through the expression of programmed 
death ligand 1.  They also lack the expression of CD40, CD80 or CD86 which are co-
stimulatory molecules needed for conventional allogeneic T-helper 1 or T-helper 2 type 
responses (Lauden et al., 2013).  However, further studies using allogeneic ckit+ stem 
cells in vivo are needed.  Studies with other types of endogenous cardiac progenitors have 
similar results.  Cardiosphere-derived cells express class I MHC antigens but not class II 
antigens or B7 co-stimulatory molecules (K. Malliaras et al., 2012).  The absence of 
MHC class II gives cells the potential to escape recognition by alloreactive CD4+ 
lymphocytes (Tasso & Pennesi, 2009).  In culture, they elicit negligible lymphocyte 
proliferation and inflammatory cytokine secretion and when transplanted in vivo into an 
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infarcted rat heart, they cause a mild local immune reaction, without histologically-
evident rejection or systemic immunogenicity with similar sustained benefits to 
syngeneic transplantation at 6 months post injection (K. Malliaras et al., 2012).  
Cardiospheres in vitro inhibited proliferation of alloreactive T cells, and interestingly 
when transplanted in vivo attenuated the inflammatory response observed histologically 
in the peri-infarct area (Tseliou et al., 2013). 
Although stem cells seem to have a low immunogenic profile, once transplanted 
they do not survive long-term (Konstantinos Malliaras et al., 2013). This may due to the 
fact that differentiated progeny of transplanted allogeneic pluripotent stem cells are 
rejected by the host immune system (Nussbaum et al., 2007).  During differentiation, 
hESC express very low levels of surface MHC1 molecules but following implantation 
they differentiate and up-regulate MHC expression thus triggering effective immune 
responses (Calderon et al., 2012).  Some would argue that although allogeneic CPCs are 
eventually rejected, much of the benefit of cell transplantation is due to indirect 
mechanisms such as paracrine secretion or activation and recruitment of existing 
endogenous stem cells. Therefore, allogeneic transplantation may still be beneficial if 
rejection is delayed long enough to allow cells to exert their protective and regenerative 
paracrine effects (K. Malliaras et al., 2012). 
Overall, endogenous cardiac progenitors are a promising cell-based therapeutic 
for the heart.  They have relative safety as there have been no adverse events such as 
cancer or arrhythmias.   Thus far, they have demonstrated a relatively low immunologic 
profile and can result in functional benefits that last 1-2 years.  Yet cells are rarely 
retained long-term. Malliaras et al demonstrated that 24 hours after intracoronary infusion 
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the percentage of cells that engrafted within the heart was 4.3% (Konstantinos Malliaras 
et al., 2013).  It is likely that enhanced engraftment could result in improvements in 
existing outcomes. The greatest benefits will most likely come from transplantation of 
carefully selected cell types that have been pre-treated for optimal functioning, within an 
engraftment promoting medium. 
 
ISL1+ Cardiac Progenitors 
One of the endogenous cardiovascular progenitor types that has yet to be used in 
clinical trials is the ISL1+ cardiac progenitor.  Islet-1 (ISL1) is a protein that is expressed 
by stem cells early during cardiovascular development and is essential for cardiogenesis; 
progenitors that express ISL1 are required for the formation of the right ventricle, atria 
and outflow tract (Cai et al., 2003).  Addition of purified ISL1 protein to human 
embryonic stem cells during differentiation, can increase the number of cardiac cells 
produced 3-fold (Fonoudi et al., 2013).   This highlights the utility of ISL1 expression in 
cardiogenesis.  In vitro, ISL1+ progenitor cells are capable of forming all three 
cardiovascular lineages (Bu et al., 2009).  Despite their clear role in cardiovascular 
development, the ability to isolate ISL1+ cardiac progenitors from the human heart 
decreases with age.  In the young heart there are abundant levels of ISL1+ progenitor 
populations, yet with increasing age, ISL1+ cardiac progenitors are reduced to reportedly 
nonexistent levels (Simpson et al., 2012).  Comparison of neonatal ISL1+ cardiac 
progenitors with similarly isolated adult progenitors that are negative for ISL1 revealed 
that, after transplantation into the infarcted myocardium, neonatal ISL1+ cardiac 
progenitors had a significantly higher ability to preserve myocardial function, prevent 
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adverse remodeling, and enhance blood vessel formation (Simpson et al., 2012).  This 
suggests that ISL1+ cardiac progenitors derived from the young heart may be more ideal 
for cardiovascular regeneration.    
In this dissertation we utilize a novel stem cell population characterized by the 
expression of both ISL1 and ckit.  In humans, this population of cells was thought to only 
exist in the fetal heart (Serradifalco et al., 2011), however, we have isolated 
cardiovascular stem cells that co-express both ISL1 and ckit from the adult heart (57-75 
year olds).  Because of the essential role of both ISL1 and ckit in cardiogenesis, the co-
expression of these markers could potentially identify a progenitor population with high 
regenerative capacity.  The fact that this vital population persists throughout life, yet, the 
aged heart still has limited regenerative capacity suggests that these cells are either too 
few in the adult heart, not activated sufficiently after injury and/or there are underlying 
biological differences between adult ISL1+ ckit+ cardiac progenitors and phenotypically-
matched cardiovascular progenitors from the young heart.  
In this dissertation we created single cell clones from our newly isolated adult 
ISL1+ckit+ cardiovascular progenitors and compared them to similarly isolated and 
cloned ISL1+ ckit+ cardiac progenitors from the neonatal (<1month old) heart.  
Comparison of single cell clones allows us to define how age impacts epigenetic, 
phenotypic, and functional parameters within ISL1+ ckit+ cardiovascular stem cells.  
This will provide a better mechanistic understanding of the superior regenerative ability 
of neonatal ISL1+ ckit+ cardiac progenitors and will provide novel therapeutic targets to 
improve myocardial regeneration. 
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In chapter 2, we will address the following hypotheses: 
Hypothesis 1: Phenotypically-matched neonatal and adult cardiovascular progenitors  
differ in their ability to invade in response to growth factor stimulation and in 
their ability to differentiate into endothelial cells and cardiomyocytes.   
 
Hypothesis 2: Superior neonatal functional ability is aided by the expression of  
microRNAs which are altered with stem cell age specifically in pathways 
influencing cell cycle progression and cellular senescence.  
 
As previously stated, full regeneration of the injured heart may not only require carefully 
selected cell types, but will most likely require optimization of cell function by 
pretreatment methods.  Therefore, in chapter 3, we will address the following hypothesis: 
Hypothesis 3: Treatment of neonatal and adult cardiovascular progenitors with short- 
term hypoxia and/or prostaglandin E2 (PGE2) will alter MAPK/ERK pathway 
activation and increase cardiac progenitor cell cycle progression, migration and 
paracrine factor expression. 
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Abstract 
Although clinical benefit can be achieved after cardiac transplantation of adult c-
kit+ or cardiosphere-derived cells for myocardial repair, these stem cells lack the 
regenerative capacity unique to neonatal cardiovascular stem cells. Unraveling the 
molecular basis for this age-related discrepancy in function could potentially transform 
cardiovascular stem cell transplantation. In this report, clonal populations of human 
neonatal and adult cardiovascular progenitor cells were isolated and characterized, 
revealing the existence of a novel subpopulation of endogenous cardiovascular stem cells 
that persist throughout life and co-express both c-kit and isl1. Epigenetic profiling 
identified 41 microRNAs whose expression was significantly altered with age in 
phenotypically-matched clones. These differences were correlated with reduced 
proliferation and a limited capacity to invade in response to growth factor stimulation, 
despite high levels of growth factor receptor on progenitors isolated from adults.  Further 
understanding of these differences may provide novel therapeutic targets to enhance 
cardiovascular regenerative capacity. 
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Introduction 
Endogenous cardiac progenitor cells (CPCs) are being carefully investigated to 
determine whether they have the ability to repair the heart when expanded in vitro and re-
administered as a cell-based treatment after myocardial infarction in human clinical trials 
(Bolli et al., 2011; Makkar et al., 2012).  As CPCs age, however, they lose the ability to 
efficiently regenerate damaged heart tissue.  Telomerase activity is reduced with 
chronological age and an associated decline in the number of functionally-competent 
cardiac progenitor cells results in a dramatic loss of growth reserve within the adult heart 
(Cesselli et al., 2011; Torella et al., 2004).  Functional studies in mice have shown that 
neonatal, not adult, c-kit+ cardiac progenitors support post-infarct myogenesis (Jesty et 
al., 2012).  The molecular basis underlying the enhanced capacity for regeneration that 
distinguishes human neonatal cardiovascular progenitor cells from adults has not been 
defined. 
As a fetus matures into a neonate, several developmental changes impact the 
CPC.  Lineage tracing studies using embryonic stem cells show that early cardiovascular 
progenitors expressing MESP1 differentiate into two separate classes of Nkx2.5+ 
progenitor populations, one characterized by the expression of Isl1 and another 
characterized by the absence of Isl1 (Bondue et al., 2011).  The Isl1+ cardiac progenitors 
can be differentiated into all three cardiac lineages including endothelial cells, smooth 
muscle cells, and cardiomyocytes (Laugwitz et al., 2005). The differentiation capacity of 
Isl1- CPCs is limited to smooth muscle cells and cardiomyocytes (Bondue et al., 2011).  
Histological analysis suggests that cells positive for Isl1, and SSEA-4 (an early stem cell 
marker) are abundant in the fetus and are only sporadically found in the neonate. Cells 
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expressing c-kit and Nkx2.5 decline in number significantly as a neonate transitions into 
an infant (Amir et al., 2008; Mishra et al., 2011).  A gradual reduction of proliferation 
occurs in the heart at this time; during the neonatal period there are 3 times as many 
proliferating cells as those identified in children >2 years of age (Mishra et al., 2011).  
After the first month of life, the dynamics of the CPC population changes dramatically, 
highlighting the neonatal window as an optimal time during which progenitor cells can be 
isolated for therapy.  The biological features that distinguish neonatal cardiovascular 
progenitor cells in humans will provide new insight that can be used to improve the 
outcome of stem cell-based treatment. 
In this report, the epigenetic, phenotypic and functional changes that distinguish 
neonatal from adult cardiovascular progenitor cells are detailed within a newly-defined 
population of Isl1, c-kit co-expressing cardiovascular progenitor cells.  By comparing 
matched, clonal cardiovascular progenitor cell populations that differ only by age, we 
identify significant differences in microRNA regulation and gene expression that 
correlate with functional limitations in the adult cardiovascular progenitor cell 
population.      
 
Results 
Phenotypic Profiling and Identification of Cardiovascular Progenitor Cell Clones 
Isolated from Human Neonates and Adults 
 The surface marker profile of cardiovascular progenitor cell clones residing 
within the heart of human neonates <1 month old and 57-75 year old adults was directly 
compared by flow cytometry (Fig. 1, Appendix; Supplementary Table 1).  Over 240 
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Figure 1. Phenotypic characterization of surface markers on neonatal and adult CPC clones.  
CPC clones from human neonates and adults were compared using flow cytometry to 
identify the surface phenotype of these cells.  Labeling for select markers on representative 
CPC are shown in the figure where positive staining above the isotype control is shown in 
black.  Each column represents a separate and representative clonal population.  The 
surface phenotype of 24 clones was examined in total.   
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cardiovascular cell clones were isolated by single cell expansion. Phenotypic profiling 
using seventeen different antibodies (Appendix; supplementary table 2), specific for 
surface antigens reported to be present on functionally competent cardiovascular 
progenitors, provided a basis for identifying comparable cardiovascular progenitor cells 
residing in the heart of both newborns and adults.  All clones expressed moderate to high 
levels of CD105 (60.6 – 99.8%), CD73 (41.0 – 98.3%), CD44 (60.6 – 99.8%), CD13 
(73.7 - 99.9%), IGF1R (58.0 – 99.1%), and CD146 (35.7 – 99.9%).  c-kit was expressed 
at lower levels (2.5 – 52.4%), and expression of KDR (0 – 75.1%), PDGFR (2.4 – 
57.9%), CD34 (4.9 – 78.8%) and SSEA4 (0 –95.7%) was variable, thereby distinguishing 
specific populations.   Interestingly, the majority of surface antigens were not expressed 
at significantly different levels in adult and neonatal cardiac progenitors.  Of the 17 
surface antigens profiled, only CD31 was expressed at significantly lower levels in adult 
cardiovascular progenitors (p=0.04). The progenitors were positive for the expression of 
HLA class I antigens (82.6 – 99.9%) and HLA class II antigens were either not expressed 
(0 - 3.9% in 21 CPC clones) or expressed at low to moderate levels (3 CPC clones 8.3%, 
28.6%, 34.1%).   
 
Coexpression of Isl1 and C-Kit on Human Neonatal and Adult Cardiac Progenitors 
 Expression of Isl1 and c-kit identifies cells with cardiomyogenic potential 
(Ferreira-Martins et al., 2012; Moretti et al., 2006).  Characterization by flow cytometry 
and PCR revealed that Isl1 and c-kit were co-expressed on CPC clones isolated from both 
neonates and adults (Fig. 2). The majority of CPC clones expressed moderate levels of c-
kit (23 ± 3% in neonates, 27 ± 3% in adults).  In neonates, Isl1 was present on most, but   
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Figure 2. Co-expression of Isl1 and c-kit on neonatal and adult cardiovascular progenitors.  
Adult and neonatal cardiovascular progenitor cell clones were examined by PCR and flow 
cytometry to determine whether Isl1 was expressed in these cells.  c-kit expression, initially 
identified by flow cytometry, was confirmed by PCR.  PCR products were run on a gel, 
transcripts for Isl1 (size=202bp) and c-kit (size=105bp) were co-expressed on both 
neonatal (A) and adult (B) cardiovascular progenitor cell clones.  Flow cytometry 
confirmed the expression of Isl1 protein (C & D) and the coexpression of Isl1 and c-kit 
protein (E) on neonatal and adult cardiovascular progenitors. 
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not all kit+ clones (78%, N=13).  In adults, cardiac progenitor clones were all c-kit+ and 
Isl1+ (N=16).   
 The Isl1+ c-kit+ neonatal and adult CPC clones were differentiated into 
cardiomyocytes using previously reported protocols (Smits et al., 2009).  Successful 
differentiation was supported by the expression of  mRNA transcripts  for NK2 
homeobox 5, gata binding protein 4, cardiac myosin light chain 2, cardiac myosin heavy 
chain alpha and troponin T, which were induced during the differentiation protocol 
(N=12, Appendix; Supplementary Fig. 1).  There were no significant differences in 
transcription of these proteins between neonatal and adult Isl1+ c-kit+ cardiovascular 
progenitors.  Cardiac progenitor cells were shown by immunocytochemistry to express 
cardiac Troponin I (Appendix; Supplementary Fig. 2). When treated with 10nM 
dexamethasone for 6 days (D'Amario, Fiorini, et al., 2011), CPCs were successfully 
differentiated into all three cardiovascular lineages as demonstrated by a shift in mean 
fluorescence intensity when the cells were treated with antibodies to identify binding to 
smooth muscle actin, von Willebrand Factor, cardiac Troponin T and cardiac Troponin I 
using flow cytometry.    
 
MicroRNA Profiling Predicts Functional Differences in Neonatal and Adult 
Cardiovascular Progenitors. 
Unique differences in epigenetic regulation emerged when comparing cardiovascular 
progenitor cell clones by microRNA profiling.  MicroRNAs (miRNAs) function to 
negatively regulate mRNA expression by either translational inhibition or degradation.  
When comparing neonatal and adult CPC clones, 41 out of 88 microRNAs analyzed were  
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Figure 3.  MicroRNA profiling and gene expression predicts functional differences when 
comparing neonatal and adult cardiovascular progenitors.  A) Heat map of 41 microRNAs 
differentially regulated in neonatal (N=8) and adult (N=3) cardiac progenitors. hESC were 
also profiled as a means for comparison. Red color identifies maximum expression, black 
color represents average expression, blue color identifies microRNAs with minimum 
expression.  Sets of co-regulated microRNAs were grouped together by RT2 Profiler PCR 
Array Data Analysis Version 3.5 software (SABiosciences).  B) MicroRNAs expressed at 
significantly different levels in adult vs. neonatal CPCs suggest that proliferation is higher 
in neonatal CPCs. MicroRNA 17, miR-20a, and miR-106b levels, positively correlated 
with proliferation, were significantly higher in neonatal CPCs (p=0.0094, p=0.0030, 
p=0.0085, respectively). C) MicroRNA-371-3p, associated with senescence, was 
expressed at significantly higher levels in adult CPCs (p=0.0238). D) Messenger RNA 
transcripts for E2F1 (N=6) and E) Myc (N=5) were significantly higher in adult 
cardiovascular progenitors (p=0.0075, p=0.0086 respectively).  E2F1 regulates the G1 to 
S transition of the cell cycle.  F)  Expression of DNA repair proteins ATM (N=5) and 
RAD50 (N=5) were significantly higher in adult CPCs (P=0.0099, P<0.0001, respectively). 
G) Representative cell cycle analysis of neonatal and adult CPCs.  H) Quantification of cell 
cycle analysis. The frequency of adult CPCs (N=5) in G1 was significantly higher than 
neonatal CPCs (P=0.0038).  The frequency of neonatal CPCs (N=5) in the S and G2 phases 
of the cell cycle was significantly higher than adult CPCs (p=0.0066, p=0.0051 
respectively).  
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expressed at significantly (P<0.05) different levels (Fig. 3a, Appendix; Supplementary 
Table 3). MicroRNA expression levels in hES-3 embryonic stem cells were also 
identified and the results are shown in Figure 3 for comparison.  The microRNA 
expression pattern of neonatal cardiac progenitors was more similar to that of human 
embryonic stem cells, highlighting a number of shared characteristics.  DIANA mirPath 
computational software identified forty-six pathways that were significantly (P<0.05) 
impacted by differentially-expressed microRNAs (Appendix; Supplementary Table 4).  
Fourteen of these pathways were relevant to proliferation, including Wnt signaling, 
MAPK signaling, p53 signaling, TGF-β signaling, VEGF signaling, and base excision 
repair. Functional differences in proliferation would be anticipated based on the 
expression of microRNAs 17, miR-20a, and miR-106b which were expressed at 
significantly higher levels in neonatal cardiovascular progenitors (Fig. 3b) (B. Li et al., 
2011; Petrocca et al., 2008; Pickering, Stadler, & Kowalik, 2009; Trompeter et al., 2011).  
High levels of expression of these microRNAs promotes cell cycle progression by 
suppressing the inappropriate accumulation of E2F1 transcription factors that lead to G1 
arrest (Petrocca et al., 2008; Pickering et al., 2009).  E2F1 regulates the G1 to S transition 
of the cell cycle to induce proliferation (Wu et al., 2001).  The 16-fold reduction in 
mRNA transcripts for E2F1 in neonatal cardiac progenitors was confirmed by RT-PCR 
(p=0.0075, Fig. 3c).  
 
Replicative Senescence in Adult Cardiac Progenitors Predicted by MicroRNA and 
Gene Expression Differences 
Replicative senescence is defined by a progressive loss in proliferative ability 
despite normal viability and metabolic activity (Morgado-Palacin, Llanos, & Serrano, 
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2012) and is associated with an increased DNA damage response and increased cell size 
(Rodier & Campisi, 2011). Several microRNAs that were highly expressed in neonatal 
CPCs are linked to proliferative ability and play a role in preventing cellular senescence.   
MicroRNAs 20a and 17, which were upregulated in neonatal CPCs (27.3 fold, P=0.0030 
and 12.5 fold, P=0.0094 Fig. 3b), function to rescue cells from Ras-induced cellular 
senescence (L. Li et al., 2012) and reduce DNA double-stranded breaks (Pickering et al., 
2009).  In contrast, microRNA-371-3p (Wagner et al., 2008), upregulated 27.9 fold 
(p=0.0238) in adult cardiovascular progenitor cells, is induced during replicative 
senescence.  Myc expression has been associated with the induction of cellular 
senescence (Campaner et al., 2010) due to DNA stress (Robinson, Asawachaicharn, 
Galloway, & Grandori, 2009).  Transcripts for Myc and DNA repair proteins, RAD50 
and ATM were significantly elevated in adult cardiac progenitors (2.9 fold, P=0.0086, 
28.5 fold, P<0.0001, 35.7 fold, P=0.0099 respectively, Fig. 3c&d).  Comparison of cell 
size by flow cytometry in three separate experiments using forward scatter gating 
demonstrated that adult cardiac progenitors had a greater percentage of large cells when 
compared with neonatal CPCs (56.3% vs. 40.2%, N=5, p=0.0073).     
 
Rate of Progression through the Cell Cycle Differs in Neonatal and Adult 
Cardiovascular Progenitors 
To further investigate the predicted proliferative differences demonstrated by 
microRNA profiling, propidium iodide (PI), a DNA intercalating agent, was used to 
identify the percentage of cells in each phase of the cell cycle.  Using flow cytometry to 
detect PI fluorescence intensity, a higher frequency of adult cardiac clones were  
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Figure 4 –MicroRNAs expressed at significantly different levels (p<0.05) impact invasion. 
MicroRNAs that both promote (A) and inhibit (B) invasion were expressed at significantly 
different levels when comparing neonatal and adult CPC by RT-PCR.  MicroRNAs that 
promote the ability to invade are transcribed at significantly higher levels in neonatal CPCs. 
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identified in G1 (82.5% vs. 63.3%, P=0.0046) and a higher frequency of neonatal clones 
were identified in S phase (19.4% vs. 7.0%, P=0.0026) and in G2 (15.0% vs. 7.5%, 
P=0.0051) (Fig. 3e).  Neonatal CPCs proliferate more actively when compared to adult 
CPCs. 
 
Cardiovascular Progenitors from Neonates and Adults Differ in Their Ability to 
Respond to Growth Factor Stimulation 
Cardiac regeneration requires CPC migration away from its stem cell niche, 
followed by invasion into the area of injury in response to external stimuli.  Nine 
microRNAs reported to regulate invasion (Aigner, 2011; Xuwei Hou et al., 2012; Jain et 
al., 2012; Ucar et al., 2010) were expressed at significantly (P<0.05) different levels in 
neonatal and adult CPCs (Fig. 4).  To investigate the possibility that neonatal and adult 
progenitors differ in their ability to invade the site of injury within the heart, transwell 
invasion assays were performed to test the response of cells to SDF-1α (stromal cell-
derived factor-1).  SDF-1α is secreted in the infarcted heart and recruits endogenous 
cardiac stem cells to the site of injury (J. M. Tang et al., 2011; Y. L. Tang et al., 2009).  
Fewer adult cardiac progenitors (6.7 x 103) were able to invade through the basement 
membrane extract when compared to neonatal CPCs (14.6 x 103, p=0.0463, Fig. 5a).  The 
inability of adult CPCs to invade in response to SDF-1α was not due to the lack of SDF-
1α receptor expression on the surface of these CPCs, as demonstrated by flow cytometry.  
The surface expression of CXCR4 and CXCR7, both of which are receptors for SDF-1α 
(Tarnowski et al., 2010), was comparable on progenitors isolated from neonates and 
adults (Fig. 5b).    
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Figure 5. Cell invasion in response to SDF-1.  A) Phenotypically similar neonatal and adult 
clones were run on a transwell invasion assay. The adult CPC clones were less invasive 
than their neonatal counterparts (n=5, run in triplicate) in response to SDF-1α, results were 
significant to P = 0.0463. B) SDF-1α receptors, CXCR4 and CXCR7, were expressed on 
both neonatal and adult cardiovascular progenitor cell clones.  Each column represents a 
separate and representative clonal population.  Isotype control labeling is shown in white, 
positive labeling is shown in black. 
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SSEA-4+ Cardiovascular Progenitors Invade More Readily 
SSEA-4 was not expressed on all CPC clones.  Inherent differences were noted in 
neonatal and adult cardiac progenitors that were found, by flow cytometry, to express 
SSEA-4.  MicroRNA profiling revealed 26 microRNAs expressed at significantly 
different levels between SSEA4+ adult and neonatal progenitors (P<0.05, Fig. 6A, 
Appendix; Supplementary Table 5).  The top ten pathways, regulated by these 
microRNAs that impact cardiovascular stem cell function are shown in figure 6b.  Six of 
these pathways impact invasion (marked with an arrow).  In functional studies, the 
SSEA-4+ progenitors were more highly invasive than SSEA4- clones within the neonatal 
cardiovascular progenitor cell population (2.0 x 104 vs 9.1 x 103, p=0.0186, Fig. 6C).  
Adult CPC clones expressing SSEA4+ were similarly more responsive to SDF-1 (8.1 x 
103 vs 3.9 x 103, p=0.0297).  SSEA4+ cardiovascular progenitors display an enhanced 
capacity to invade infarcted tissue in response to injury.  
 
Discussion 
In the present study, Isl1+ c-kit+ cardiovascular progenitor cells, identified in 
both human neonates and adults, were expanded as clonal populations and utilized as a 
resource to unravel the  phenotypic and epigenetic features that distinguish neonatal and 
adult cardiac progenitors.    
This population of cells was not previously described within the endogenous 
cardiovascular progenitor cell population in adult humans and challenges current dogma 
suggesting that Isl1+ CPCs are abundant only in the fetal or neonatal heart (X.   Hou et 
al., 2012; Simpson et al., 2012).  Previous reports comparing neonatal and adult  
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Figure 6 – SSEA-4 separates cardiovascular progenitors by the ability to invade.  A) Heat 
map of 26 microRNAs whose expression was differentially regulated in SSEA4+ neonatal 
and adult cardiovascular progenitors (p<0.05).  Red color identifies microRNAs with 
maximum expression, black color indicates average expression, blue color shows 
microRNAs with minimum expression.   Sets of similarly expressed microRNAs are 
grouped together by RT2 Profiler PCR Array Data Analysis Version 3.5 software 
(SABiosciences). B) MicroRNAs expressed at significantly different levels when 
comparing SSEA4+ adult and neonatal CPCs were analyzed using DIANA mirPATH 
software.  The top ten pathways that impact cardiovascular stem cell function, and are 
regulated by these microRNAs, are shown.  Six of the top ten pathways impact invasion 
and are marked with an arrow.  The red line denotes significance of P=0.05. C) The 
invasive response of SSEA4+ neonatal and adult cardiovascular progenitor cell clones, run 
on a transwell migration assay, was compared.  Both SSEA4+ neonatal and adult CPCs 
were significantly more responsive to SDF-1α when compared to SSEA4- neonatal and 
adult CPC, respectively (P=0.0186, P=0.0297).   SSEA4+ neonatal cardiovascular 
progenitor cell clones were most responsive to SDF-1.  These cells were significantly more 
invasive when compared to both SSEA4+ adult and SSEA4- neonatal CPC clones 
(p=0.0183, p=0.0186).  
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cardiosphere-derived cells (CDCs) for  Isl1 expression indicated that Isl1 is abundant in 
neonatal CDCs but not in CPCs isolated from adults (36.2% of neonatal CPCs versus 
3.2% adult CPCs) (Simpson et al., 2012).  Cardiac progenitors co-expressing c-kit and 
Isl1, identified in the fetal heart (Serradifalco et al., 2011), have not been isolated from 
the adult myocardium.  Stem cells isolated from the adult heart were reported to have no 
overlap in expression of c-kit and Isl1 (0.01% coexpression by flow cytometry) (Itzhaki-
Alfia et al., 2009).  The very existence of an Isl1+ c-kit+ progenitor in human adults has 
been questioned (Sussman, 2012).  Our results demonstrate, for the first time, that the 
Isl1+ c-kit+ cardiac progenitor phenotype exists in both the neonatal and adult human 
heart.  As in the embryonic heart (Serradifalco et al., 2011), all progenitors that expressed 
Isl1 expressed c-kit, however not all c-kit+ cells expressed Isl1, suggesting that the Isl1+ 
c-kit+ progenitor may be a subpopulation of c-kit+ progenitors.  PDGFR and IGF1R, 
which are present on subpopulations of c-kit+ progenitors with superior regenerative 
capacity (D'Amario, Cabral-Da-Silva, et al., 2011; Hidaka et al., 2010), were expressed at 
moderate to high levels on these cells.   
HLA Class II antigens were not expressed on the majority of neonatal and adult 
CPC clones.  MHC class II expression activates acute T-cell mediated graft rejection 
(Pietra, Wiseman, Bolwerk, Rizeq, & Gill, 2000).  Allogeneic transplantation of class I 
positive, class II negative cardiac progenitors would be expected to elicit a minor, but 
transient local immune response (Malliaras et al., 2012).   
Based on findings reported here, the capacity for cardiac regeneration after 
transplantation of CPCs in neonates and adults is impacted by underlying differences in 
epigenetic regulation.  Forty-one microRNAs were expressed at significantly different 
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levels as a consequence of age.  Pathways significantly impacted by these microRNAs 
fell into broad categories such as proliferation (ex. p53 signaling, base excision repair, 
MAPK signaling) and migration/invasion (ex. Regulation of Actin Cytoskeleton, TGF-β 
signaling, VEGF signaling) suggesting that regulatory mechanisms governing these 
processes differed significantly in neonatal and adult progenitors. In rodents, microRNA 
profiling similarly identified mechanisms by which a proliferative difference occurs when 
comparing neonatal and adult CPCs (Sirish et al., 2012).  Human embryonic CPCs 
directly isolated from the heart without culture have a proliferative advantage over adult 
CPCs (Sirish et al., 2012).  Our studies take this work a step further by using matched 
clonal populations to document distinct differences in microRNA expression when 
comparing neonatal and adult human cardiovascular progenitor cells.  
A possible mechanism for decreased proliferation in adult cardiac progenitors is 
complex regulation of the Myc-E2F1 axis by microRNAs leading to an increase in 
cellular senescence.  E2F1 is a transcriptional activator that is important in the G1/S 
transition; inappropriate accumulation of E2F1 increases DNA damage response and 
significantly impacts the ability of cells to enter the S phase of the cell cycle (Pickering et 
al., 2009).  High levels of Myc expression may result in senescence by initiating cellular 
stress (Campaner et al., 2010). This stress leads to upregulation of DNA repair proteins 
and cell cycle arrest (Robinson et al., 2009), both of which were observed in adult cardiac 
progenitors.  MicroRNA-371-3p, which was highly expressed in adult CPCs, is correlated 
with induction of senescence (Wagner et al., 2008).  Pro-proliferative microRNAs such 
as miR-106b, mir-20a, and mir-17 also play a role; these microRNAs help reduce G1 
arrest through regulation of E2F1 transcription factors (Pickering et al., 2009; Trompeter 
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et al., 2011).  Transcripts for all three microRNAs were significantly elevated in neonatal 
CPCs and mir-17 and mir-20a are directly regulated by Myc expression (Coller, Forman, 
& Legesse-Miller, 2007; Pickering et al., 2009).   
MicroRNA profiling and pathway analysis also predicted differences in the 
capacity to invade, results that were confirmed in vitro.  Fewer adult CPCs responded to 
SDF-1α, despite having adequate CXCR4 and CXCR7 receptor levels on their surface.  
SDF-1α is secreted in the damaged heart and recruits both exogenous and endogenous 
cardiovascular stem cells to the site of injury (Y. L. Tang et al., 2009).  Interestingly, not 
all neonatal and adult cardiac progenitors responded equally to SDF-1α; we identified a 
subpopulation of neonatal and adult progenitors that expressed SSEA-4.   SSEA-4 is a 
stem cell marker that identifies cells in early stages of progenitor development 
(Henderson et al., 2002).  In our study, SSEA-4 expression was correlated with 
differential expression of microRNAs involved in invasion-related pathways.  SSEA-4 is 
expressed on cancer cells that are more highly invasive (Van Slambrouck & Steelant, 
2007), however little is known about the impact of SSEA-4 on SDF-1α-induced invasion 
in cardiovascular cells.  Our study shows that SSEA-4+ progenitors invaded more readily 
in response to SDF-1α when compared to their SSEA-4- counterparts.  Comparison of 
SSEA4+ neonatal and adult CPCs demonstrated that age negatively impacts invasion.  
There may be several reasons for this age-related functional discrepancy.  SDF-1α 
signals primarily through Akt signaling or ERK1/2 signaling.  Depending on the cell 
type, these pathways can signal independently, one regulating the survival and 
proliferation functions of SDF-1 signaling, the other regulating invasion and migration 
(Peng et al., 2005).  After activation by SDF-1α, CXCR4 dimerizes and is phosphorylated 
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by JAK2 and JAK3 which create docking sites for transcription factors to propagate 
signaling (Vila-Coro et al., 1999).  Adult CPCs may demonstrate decreased CXCR4 
dimerization, reduced numbers of cosignaling molecules, or lower levels of 
phosphorylation and activation of the receptor.  Additionally, the cells themselves may 
secrete different levels of growth factors which could contribute to lower levels of 
receptor activation.  
MicroRNAs play a role in SDF-1α signaling and invasion. Significant differences 
in microRNA expression in aged cardiac progenitors influences functional parameters 
relevant for cardiovascular repair.  For example, activation of the SDF-1α receptor, 
CXCR4, induces the expression of proteases such as matrix metallopeptidase 9 (MMP9) 
which help to degrade the extracellular matrix, allowing cells to invade (Yu et al., 2011).  
The expression of MMP9 is inhibited by miR-132 (Ucar et al., 2010) and miR-206 (H. 
Liu, Cao, Ye, & Sun, 2010). The expression of these microRNAs were significantly 
upregulated in adult CPCs when compared with their expression level in neonatal CPCs 
(6.0 fold, p=0.0005, 9.6 fold, p=0.0166 respectively).  Inhibitors of invasion, such as 
metallopeptidase inhibitor (TIMP3) (Jain et al., 2012) and homeo box A5 (HOXA5) (X. 
H. Liu et al., 2012) are targeted by microRNAs upregulated in neonatal cardiac 
progenitors.  MicroRNA-103 represses the expression of TIMP-3 (Jain et al., 2012) 
(elevated 8.7 fold in neonatal CPCs, p=0.0027) and microRNA-130a represses the 
expression of HOXA5 (Chen & Gorski, 2008) (elevated 2.4 fold in neonatal CPCs, 
p=0.0288).  If adult progenitors cannot effectively invade the site of injury, a dramatic 
difference in regeneration will occur with age.   
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MicroRNA-mediated regulation of gene expression is a novel, rapidly expanding 
area of research which has opened up new therapeutic options for the reversal of heart 
disease.   Pretreatment of cardiac progenitors prior to transplantation, or direct 
administration into the heart may activate stem cell recruitment from endogenous 
sources.  In neonatal rodents, microRNA mimics had a positive effect on cytokinesis, 
DNA synthesis, and cell cycle re-entry (Eulalio et al., 2012).  MicroRNAs whose 
expression levels are altered in aged CPCs may be manipulated in vivo to promote 
recovery from myocardial damage.  For example mir-24 (upregulated 8.4 fold in neonatal 
CPCs) when introduced after myocardial infarction reduces infarct size (Boregowda et 
al., 2012). Conversely, inhibition of mir-208a (upregulated 12.4 fold in adult CPCs) 
reduced cardiac remodeling, improved cardiac function, and survival after hypertension-
induced heart failure (Abdelalim & Tooyama, 2012). The potential for microRNA-based 
therapeutics to promote stem cell mobilization, combined with an understanding of the 
role of microRNAs in cardiac regeneration, promises to open up new treatment options 
that may improve the outcome of stem cell-based therapies.  
Cardiovascular progenitor cells co-expressing c-kit and Isl1 can be identified and 
expanded in vitro from neonatal and adult heart tissue.  Epigenetic differences highlight 
the mechanism by which neonatal cardiovascular progenitor cells can proliferate and 
invade in response to cytokine stimulation, whereas the adult cells have a diminished 
capacity for mobilization.   Neonatal cardiac progenitor cell clones expressing SSEA-4 
are more responsive to stimulation and may be optimal for cardiac regeneration.   
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Methods 
Ethics Statement/ Cell Isolation and Expansion 
 The Institutional Review Board of Loma Linda University approved the protocol 
for use of tissue that was discarded during cardiovascular surgery, without identifiable 
private information, for this study with a waiver of informed consent. Discarded atrial 
cardiac tissue from human neonates (<1 month old) and adults (57-75 years old), was cut 
into small clumps (approximately 1mm3) and collagenase digested (Roche Applied 
Science, Indianapolis, IN) for approximately 2 hours at 37 degrees at a proportion of 
1:2.5 tissue volume vs. collagenase.  This solution was then passed through a 40μm cell 
strainer to isolate cardiac progenitors (Smits et al., 2009).  Resulting cells were cloned by 
limiting dilution at a concentration of 0.8 cells per well to create clonal populations 
which were expanded for further study.  Over two hundred and forty clones were isolated 
from human patients by this procedure; seventeen neonatal and sixteen adult 
cardiovascular cell clones were compared in detail for this study. The human embryonic 
stem cell line hES-3 was cultured as previously published (Kearns-Jonker et al., 2012).  
Cardiac progenitor cell clones were differentiated both by treatment with 5-azacytidine 
followed by ascorbic acid and TGF- β to induce cardiomyogenic differentiation (Smits et 
al., 2009) and by treatment with 10nM dexamethasone in DMEM/F12 media 
supplemented with 10% fetal bovine serum to induce differentiation into all three 
cardiovascular lineages (D'Amario, Fiorini, et al., 2011).  Cardiomyogenic differentiation 
was confirmed by measuring the induction of mature cardiac-specific transcripts by RT-
PCR.  Expression of endothelial, smooth muscle, and cardiomyocyte markers induced by 
dexamethasone treatment were quantified by flow cytometry.   
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Flow Cytometry Experiments 
 Cells were labeled using antibody concentrations that were recommended by the 
manufacturer(s).  Fluorescently labeled cells were analyzed using a MACSquant analyzer 
(Miltenyi Biotec, Auburn, CA).  FlowJo software (Ashland, OR) was used for 
quantification.  Dead cells and small particles were gated out using forward-scatter, side-
scatter gating.  Isotype controls (MS IgG1) were used to define negative and positive 
populations.  Antibodies used included CD105-PE, IGF1R-PE, CXCR4-PE, CXCR7-PE, 
CD140a-PE, CD146-PE, SSEA-4-FITC, Pan HLA-FITC, CD309-PerCP/Cy5.5 
(Biolegend, San Diego, CA), CD44-FITC, CD13-PE, CD31-PE, HLA-Dr-PE, CD73-PE, 
CD34-PE (BD Biosciences San Jose, CA), CD90-PE (Immunotech, Brea, CA), CD117-
PE (Millipore, Billerica, MA).  Additional antibody data can be found in appendix; 
supplementary table 2. Relative percentage of large neonatal and adult cardiovascular 
progenitors was assessed by flow cytometry.  Large cells were defined by forward scatter 
gating that was uniformly applied to all samples and the percentage of cells within this 
gate was compared. Each test was run in duplicate. 
 
RT-PCR 
 Total RNA was extracted from neonatal and adult cardiovascular progenitor cell 
clones and reverse transcribed into cDNA using superscript III (Invitrogen, Grand Island, 
NY). Real-time PCR was performed using Go Taq® Green Master Mix (Promega, 
Madison, WI). The PCR conditions were: 94°C for 10 minutes, 94°C for 15 seconds, 
56°C for 60 seconds, 72°C for 30 seconds for a total of 40 cycles. Human primers were 
created using NCBI primer blast and included tyrosine-protein kinase (c-kit), 
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and ISL LIM homeobox 1 (Isl1).  
Primer sequences are listed in appendix; supplementary table 6.   
 For microRNA profiling experiments, total RNA was extracted from 
representative neonatal (N=8) and adult (N=3) CPC clones and converted to cDNA using 
the RT2 miRNA First Strand Kit (SABiosciences, Valencia, CA).  The Cell Development 
& Differentiation miRNA PCR array plates (SABiosciences, Valencia CA) and RT2 
SYBR Green qPCR Mastermix (SABiosciences, Valencia, CA) was used.  Plates were 
run on an iCycler iQ5 PCR Thermal Cycler (Bio-Rad, Hercules, CA) for 94°C for 10 
minutes, 94°C for 15 seconds, 60°C for 60 seconds, 72°C for 30 seconds for a total of 40 
cycles.  Fold change was calculated using the ΔΔCt method(Rodier & Campisi, 2011).  
Data from representative cardiovascular cell clones was analyzed individually, then 
pooled within age groups.  The microRNA expression data has been deposited in NCBI’s 
Gene Expression Omnibus (Edgar, Domrachev, & Lash, 2002) and are accessible through 
GEO series accession number GSE49235.  miRNAs that were expressed at significantly 
different levels when comparing neonatal CPC with adult CPC were analyzed using 
DIANA mirPath computational software (Athens, Greece) which performs an enrichment 
analysis of multiple microRNA target genes, comparing each set of microRNA targets to 
all known KEGG pathways (T. M. Liu et al., 2013).   
 
Cell Cycle Analysis 
 Cells were trypsinized at 60-80% confluency, counted, and concentrated to 105 
cells/0.3ml PBS.  Ethanol (0.7ml) was added dropwise to fix the cells.  Cells were stored 
for at least 1 hour at -20 degrees, washed, incubated at 37 degrees with RNase A 
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(0.5mg/ml Invitrogen, Grand Island, NY) and propidium iodide was then added at a final 
concentration of 10μg/ml. Samples were run on MACSquant analyzer (Miltenyi BIotec, 
Auburn, CA).  Cell cycle analysis was done using FlowJo software (Ashland, OR).  
 
Transwell Invasion Assay 
 Cells were plated in the top well of Costar Transwell plates (8μm pores), coated 
with Cultrex™ basement membrane extract (Trevigen, Gaithersburg, MD) mimicking 
extracellular matrix.  Cells were plated at a density of 100,000 cells per 100μl in starved 
medium.  Stromal cell-derived factor-1α (SDF-1α, Invitrogen, Grand Island, NY) was 
used as a chemoattractant at a concentration of 100ng per ml of M199 plus EGM-2 in the 
bottom chamber of a transwell plate.  After 24 hours, cells in the bottom wells were 
trypsinized and counted using a flow cytometer. The response of neonatal and adult CPC 
clones was analyzed individually then pooled by age and subdivided according to the 
presence or absence of SSEA-4 expression.    
 
Immunocytochemistry 
 Neonatal and adult CPC were plated on gelatin coated Lab-Tek II cc2 chamber 
slides (Nunc, Rochester, NY) and grown at 37º for 4 days, fixed in 4% paraformaldehyde 
and stained using a primary anti-troponin I antibody at 10μg/ml (Millipore #MAB1691, 
Billerica, MA) and FITC-conjugated, goat anti-mouse IgG secondary antibody at 2μg/ml 
(Southern Biotech, Birmingham, Alabama).  Coverslips were mounted using Prolong 
Gold antifade with DAPI (Invitrogen, Grand Island, NY).  Slides were imaged using a 
Zeiss confocal LSM 710 NLO laser-scanning, confocal microscope (GmbH, Germany). 
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Statistics 
 RT2 Profiler PCR Array Data Analysis software (SABiosciences, version 3.5) was 
used to calculate statistical significance for microRNA profiling.  Data was tested for 
normal distribution using the Anderson-Darling normality test calculator Version 6.0 
with an alpha of 0.05 (faculty.missouri.edu/~glaserr/3700s11/AD-Test_Calculator.xls).  
For normally distributed data, an unpaired, two-tailed student's t test was performed. For 
data that was not normally distributed, a Mann-Whitney Rank Sum Test was performed.  
Statistically significant differences were identified as P < 0.05. Data was reported as the 
mean +/- standard error. 
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CHAPTER THREE 
INVESTIGATION OF A NOVEL THERAPEUTIC STRATEGY TO IMPROVE 
ENDOGENOUS CARDIAC STEM CELL FUNCTION 
 
Introduction 
The ERK signaling pathway is the classical mitogen-activated protein kinase 
signaling pathway that is stimulated by a variety of growth factors including SDF-1α (Hu 
et al., 2007; Yin et al., 2011).   Changes in the phosphorylation of ERK can have 
functional consequences on cell proliferation, invasion, and secretory phenotype (Howe, 
Aplin, & Juliano, 2002; H. J. Lee, Cho, Kwon, Park, & Kim, 2013; Xie et al., 2014). 
ERK signaling is required for cardiosphere formation and subsequent VEGF production, 
and inhibition of ERK results in increased levels of stemness associated genes such as 
OCT4 (Cho et al., 2012).  Tight regulation of the ERK signaling pathway in CPCs is 
essential, as small increases in phosphorylation can result in functional benefits whereas 
large increases in ERK phosphorylation are associated with replicative senescence (Choi 
et al., 2013).  Duration and intensity of ERK phosphorylation can also impact 
downstream functional consequences (Murphy & Blenis, 2006).   
In this chapter we investigated the potential for a novel combination of short-term 
hypoxia and prostaglandin E2 treatment to improve endogenous CPC function through 
regulation of the MAPK/ERK signaling pathway.  There is evidence that treatment of 
with a combination of hypoxia and PGE2 can result in additive functional improvements 
(Jung, Choi, Yoo, Baek, & Kwon, 2013) through overlapping signaling.  In human cancer 
cells, 24 hours of hypoxia (1% oxygen) activated the cyclooxygenase-2-PGE2 synthase 
axis (J. J. Lee et al., 2010).  Conversely, treatment with PGE2 induced hypoxia-inducible 
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factor-1α (HIF-1α) stabilization and nuclear localization (X. H. Liu et al., 2002).  In 
endothelial cells, exogenous administration of PGE2 augmented hypoxia-induced 
proliferation and VEGF secretion (Zhao et al., 2012) and in hematopoietic stem cells, 
increased HIF-1α was required for increased migration through PGE2 mediated 
upregulation of CXCR4 (Speth, Hoggatt, Singh, & Pelus, 2014).  Both migration and 
invasion are important CPC functions required for cardiac regeneration.  In response to 
external stimuli, cardiac progenitors must first migrate through the blood and 
extracellular fluid towards the site of injury.  Once at the site of injury, CPC must then 
invade, through the use of proteases and other proteins and infiltrate the injured area.  In 
this chapter, we report the response of neonatal and adult cardiovascular progenitors 
treated with short-term hypoxia and prostaglandin E2.  We measured the relative 
phosphorylation of ERK and the functional consequences of altered signaling after cell 
treatment, specifically, cell cycle progression, expression of paracrine factors, and 
migration.   
The portion of this work that was prepared for publication is included in this 
chapter.  The data summarizing the treatment of cells with hypoxia alone and treatment 
of cells with a combination of hypoxia and prostaglandin E2 is included in the appendix.  
In brief, exposure to hypoxia (1% oxygen) increased the phosphorylation of ERK 
(Appendix, supplementary figure 3) and combination of prostaglandin E2 with hypoxia 
further increased the phosphorylation of ERK (Appendix, supplementary figure 4).  
Migration, which was not altered by hypoxia exposure, was increased with a combination 
of prostaglandin E2 and hypoxia when compared with untreated cells (9803 vs 1987 cells, 
p=0.07, appendix, supplementary figure 5). Cell cycle progression, on the other hand was 
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not significantly altered by either hypoxia treatment alone or a combination of hypoxia 
and prostaglandin E2 (Appendix, supplementary figure 6).  Therefore, the combination of 
prostaglandin E2 with hypoxia can increase CPC ERK phosphorylation and migration 
when compared with hypoxia treatment alone.   
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Abstract 
Prostaglandin E2 improves functional outcome when injected into the heart or co-
transplanted with stem cells after a myocardial infarction.  This effect may be mediated 
through activation of select populations of existing stem cells.    The signaling and 
functional events associated with treatment of human endogenous cardiac stem cells with 
prostaglandin E2 is unknown.  In this report we used clonal populations of Islet-1+ c-kit+ 
cardiac stem cells that were derived from the human heart to study the effect of 
prostaglandin E2 on migration, cell cycle progression, gene expression and signaling. 
Islet-1+ c-kit+ cardiac progenitors expressed transcripts for prostaglandin receptors EP1, 
EP2, and EP4 but not EP3 by PCR.  A significant increase in migration of cardiac 
progenitors was identified after 24 hours of prostaglandin E2 treatment, using a transwell 
migration assay.  On the other hand, cell cycle progression (as measured by flow 
cytometry) was unchanged and differentiation along the cardiac specific lineage as 
identified by transcripts for troponin T and myosin light chain 2v was not significantly 
induced by a short term exposure to prostaglandin E2.  Transcripts for genes encoding 
paracrine factors that play a key role in cardiac stem cell regenerative ability, including 
insulin-like growth factor 1, stromal cell-derived factor 1α, and vascular endothelial 
growth factor A, were expressed at significantly lower levels in endogenous cardiac 
progenitors following prostaglandin E2 treatment.  Phosphorylation of ERK and the 
prosurvival protein, AKT, was also reduced.  Our studies show that prostaglandin E2 
treatment for 24 hours improves Islet-1, c-kit+ progenitor cell migration but reduces 
cytokine expression and the activation of key pathways involved in cardiac stem cell 
regenerative ability. 
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Introduction 
The inability of the adult human heart to completely repair itself after injury, and 
the growing number of patients with heart disease, has fueled the investigation of stem 
cell-based therapeutics to enhance cardiac regeneration.  Recent clinical trials using 
endogenous cardiac stem cells administered after myocardial infarction have 
demonstrated some benefit following transplantation, however outcomes are varied and 
do not completely ameliorate dysfunction (Bolli et al., 2012; Malliaras et al., 2014).  Pre-
treating stem cells prior to transplantation can lead to increased cardiac regeneration after 
myocardial infarction (Hahn et al., 2008; Li et al., 2010)  and several approaches have 
been taken to optimize stem cell function in vitro.  One concept is to harness the innate 
response to injury as a means of developing new methods that may further enhance 
regeneration.  For example, in response to cellular injury such as myocardial infarction, 
prostaglandin E2 is secreted within the infarct zone.  Prostaglandin E2 (PGE2) is a lipid 
compound derived from arachidonic acid through a reaction catalyzed by COX-2.  
Although prostaglandin E2 is immunomodulatory (Dhingra et al., 2013; Kalinski, 2012) 
and has been shown to promote tolerance when co-transplanted with stem cells into the 
heart (Dhingra et al., 2013),  there is evidence that it may also facilitate cardiac repair 
(Xiao et al., 2004).  After myocardial infarction, injection of prostaglandin E2 increases 
the number of cardiomyocytes in the border zone (Hsueh, Wu, Yu, Wu, & Hsieh, 2014), 
whereas knockout of prostaglandin receptor EP4 increases infarct size (Xiao et al., 2004) 
and microsomal deletion of prostaglandin E2 synthase-1 impairs restoration of left 
ventricular systolic and diastolic function (Degousee et al., 2008).  Prostaglandin E2, 
therefore, is crucial to repair and may play a role in activating endogenous stem cells.  
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We hypothesized that pretreatment of cardiac stem cells with PGE2 prior to 
transplantation may enhance their regenerative capacity.   
We have previously identified an early cardiovascular progenitor cell population 
that can be isolated from the human heart and expresses both the early stem cell marker 
Islet-1 (Isl-1) as well as tyrosine protein kinase, c-kit (Fuentes et al., 2013).  In this 
report, we characterized the effect of prostaglandin E2 on gene expression, signaling, cell 
cycle progression and migration in clonal populations of human Isl-1+c-kit+ cardiac 
progenitor cells (CPCs). 
 
Materials and Methods 
Ethics Statement/Cell Isolation and Expansion 
The Institutional Review Board of Loma Linda University approved the protocol 
for use of tissue that was discarded during cardiovascular surgery, without identifiable 
private information, for this study with a waiver of informed consent. All experiments 
were performed according to the principles expressed in the Declaration of Helsinki.  
Discarded cardiac tissue from the right atrium was cut into ~1mm3 clumps then incubated 
at 37oC for 2 hours with collagenase (Roche Applied Science, Indianapolis, IN).  This 
solution was then passed through a 40µM cell strainer to isolate cardiac progenitors 
(Smits et al., 2009).  To create clonal populations for further study, cells were grown at a 
concentration of 0.8 cells/well and expanded for further study.   
 
Prostaglandin E2 Dilution 
Lyophilized prostaglandin E2 (Cayman Chemical, Ann Arbor, MI) was dissolved 
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in DMSO at a concentration of 10mM and stored at -20oC.  Prior to adding PGE2 to cell 
culture medium, the pH of the media was adjusted to approximately 6.8-7.0. 
 
Cell Cycle Progression 
To investigate relative cell cycle progression, cells were treated for 24 hours with 
normal growth medium supplemented with 10µM PGE2.  After 24 hours, cells were 
trypsinized and counted.  One hundred thousand cells were fixed in 70% ethanol, 
incubated at 37oC with RNAse A (0.2mg/ml, Fisher Scientific Pittsburg, PA), then 
labeled with propidium iodide.  Stained samples were run on a MACSquant analyzer 
(Miltenyi Biotec, Auburn, CA) and analyzed using Flowjo software. 
 
Flow Cytometry 
We used flow cytometry to measure phosphorylated proteins. Quantitation of 
phosphorylated proteins by flow cytometry is consistent with data obtained by the more 
conventional western blot technique and has the added advantage of being able to assess 
phosphorylation levels on single cells (Abrahamsen & Lorens, 2013; Jun, Lee, Song, 
Mansfield, & Chou, 2011; Krutzik & Nolan, 2003).  This technique can also determine 
whether or not the level of response is homogenous within the population (Krutzik, Irish, 
Nolan, & Perez, 2004).  Cardiovascular progenitor cell clones were grown for 24 hours in 
starving medium then treated with 10µM PGE2 for 15 minutes.  Following treatment, 
cells were trypsinized, fixed with 4% paraformaldehyde, permeabilized with 90% 
methanol, and labeled with antibodies against phosphorylated ERK 1/2 (Thr202/Tyr204, 
Cell Signaling Technology, Danvers, MA) at a 1/200 dilution or pAKT (Ser473, Cell 
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Signaling Technology, Danvers, MA) at a 1/100 dilution. FITC-labeled goat anti-rabbit 
IgG (BD Biosciences San Jose, CA) at a dilution of 1/150 was used as a secondary 
antibody.  After antibody incubation, cells were analyzed using MACSquant analyzer 
(Miltenyi Biotec, Auburn, CA).  Small particles and dead cells were gated out using 
forward-scatter, side-scatter gating.  FlowJo software (Ashland, OR) was used for 
quantification. 
 
Migration 
Migration experiments were performed after CPCs were grown in normal growth 
medium supplemented with 10µM PGE2 for 24 hours.  Cardiac progenitors were then 
trypsinized, counted and plated at a density of 50,000 cells per well in a 96 well transwell 
migration assay with 8 micron pores (Corning, Union City, CA).  Migration experiments 
were performed according to manufacturer’s instructions.  In brief, CPCs were 
resuspended in starving medium and plated in the top chamber.  Normal growth medium 
supplemented with 100ng/mL of SDF-1α (Life Technologies, Grand Island, NY) was 
used as a chemoattractant in the bottom chamber.  After 6 hours, migrated cells in the 
bottom chamber were stained using Calcein AM (Fisher Scientific Pittsburg, PA) and 
fluorescence was measured using a FLX800 fluorescent plate reader (Bio-Tek, Winooski, 
VT).  Fluorescence was converted to cell number using a standard curve as per 
manufacturer’s instructions. 
 
Quantitative RT-PCR 
Trizol reagent (Life Technologies, Grand Island, NY) was used to store cells after 
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PGE2 treatment (10µM for 24 hours).  RNA was isolated using the RNeasy Mini-spin 
Columns (Qiagen, Valencia, CA) and 500ng of RNA was used to make cDNA using the 
Superscript III protocol (Life Technologies, Grand Island, NY).  Beta actin was used as a 
housekeeping control.  RT-PCR was run on an IQ5 machine (Bio-rad, Hercules, CA).  
The PCR conditions were: 94°C for 10 minutes, 94°C for 15 seconds, 56°C for 60 
seconds, 72°C for 30 seconds for a total of 45 cycles or 94°C for 10 minutes, 94°C for 15 
seconds, 55°C for 60 seconds, 72°C for 30 seconds for a total of 45 cycles.  Primer 
sequences can be found in appendix, supplementary table 7.  Fold change was derived 
using the ∆∆Ct Method (Schmittgen & Livak, 2008).  
 
Statistics 
A paired student’s t test was used to calculate significance in cell cycle, 
migration, and flow cytometry experiments.  A student’s t test was used for RT-PCR 
experiments.  Significance was set at p<0.05.  Data is represented as the mean +/- the 
standard error. 
 
Results and Discussion 
The vital role of prostaglandin E2 in heart regeneration (Degousee et al., 2008; 
Hsueh et al., 2014; Xiao et al., 2004) lends credence to the idea that PGE2 can activate 
the human cardiac progenitor population.  However, this has not been thoroughly 
investigated.  It is unknown whether the majority of benefits after prostaglandin E2 
administration are mediated through direct activation of existing stem cells within the 
heart, or are mediated through other cell types.  In this study, we used clonal populations  
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Fig. 7. Cell cycle progression after 24 hour treatment of cardiac progenitors with 10µM 
PGE2.  A) Representative histogram of cell cycle progression in a cardiac progenitor cell 
clone.  B) Quantification of cell cycle analysis.  There was no significant difference in the 
cell cycle progression in cardiac progenitor cell clones (n=4) after 24 hours of 10µM PGE2 
treatment. 
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of human endogenous cardiac progenitors that co-express both c-kit and Isl-1 to elucidate 
whether PGE2 could be used as a pretreatment to improve CPC function.   The use of 
single cell clones with a clearly defined phenotype (Fuentes et al., 2013) allows us to 
correlate functional response after PGE2 exposure to a single cell type that normally 
resides within the heart.   
Methods to promote efficient cardiac regeneration will ideally optimize functions 
such as cell proliferation and migration.  The ability of stem cells to effectively divide 
and repopulate damaged tissue is key to their capacity for cardiac repair.  We measured 
the effect of PGE2 treatment on proliferation of Isl-1+c-kit+ cardiac progenitors using a 
flow cytometry-based approach.  After 24 hours, 10µM PGE2 treatment did not alter the 
percentage of dividing cells.  There was no significant change in the frequency of cells in 
G1, S, or G2 phase of the cell cycle (n=4, Fig. 7).  This outcome is consistent with results 
from other studies using other cell types, such as neuroectodermal stem cells that do not 
demonstrate changes in cell proliferation after PGE2 treatment (Wong, Ahmad, Li, & 
Crawford, 2014).  By and large, the cellular response to PGE2 appears to be dependent on 
variables that include cell source, cell type and dose of PGE2.  In certain populations of 
mesenchymal stem cells, treatment with 10µM of PGE2 for 24 hours increases 
proliferation (Jang et al., 2012).  In other cell types, proliferation is inversely related to 
dose, high doses of prostaglandin E2 decreases proliferation and low doses increases 
proliferation (Kleiveland, Kassem, & Lea, 2008; Zhang & Wang, 2014).  It is important 
to note that cell cycle progression, although unchanged, was not adversely affected by 
prostaglandin E2 treatment. 
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Fig. 8. Migration after PGE2 treatment in cardiac progenitor cell clones.  Treatment with 
10µM PGE2 significantly altered cardiac progenitor cell migration after 24hrs (n=4, 
p=0.049) but not after 6 hours (n=4, p=0.32). 
  
96 
Migration is also key to regeneration.  After injury, cardiac progenitors must 
migrate away from the stem cell niche towards the site of injury.  One of the factors that 
can induce CPC migration after myocardial infarction is SDF-1α (J. M. Tang et al., 
2011).  Previously, we have demonstrated that Isl-1+c-kit+ cardiac progenitor cell clones 
have ample expression of the SDF-1α receptor responsible for cell migration, CXCR4 
(Fuentes et al., 2013).  We therefore tested the effect of prostaglandin E2 on migration of 
human Isl-1+c-kit+ cardiac stem cells in response to normal growth medium 
supplemented with SDF-1α.  We compared the effect of both a 6 hour, and a 24 hour 
treatment with 10µM PGE2.  As with other cell types (Hoggatt, Singh, Sampath, & Pelus, 
2009; X. H. Liu et al., 2002; Speth et al., 2014; Weller et al., 2007), prostaglandin E2 
significantly increased SDF-1α-induced migration of Isl-1+c-kit+ cardiac stem cells after 
24 hours (9.7x103 cells, PGE2-treated CPCs vs 6.7x10
3 cells, untreated CPCs, n=4, 
p=0.049, Fig. 8).  A six hour treatment, however, did not alter cell migration (6.1x103 
cells, PGE2-treated CPCs vs 5.5x10
3 cells, untreated CPCs, n=4, p=0.32, Fig. 8), 
suggesting that time may be a factor in stem cell activation.  The increased chemotaxis of 
CPCs after PGE2 treatment may explain the elevated expression levels of stem cell 
markers (noted by others) within the heart after prostaglandin E2 injection in mice (Hsueh 
et al., 2014).  This suggests that prostaglandin E2 may play a role in homing resident 
cardiac stem cells to the site of injury and could hypothetically be used as a pretreatment 
to increase cell migration. 
There are four receptors for prostaglandin E2 including EP1, EP2, EP3, and EP4.  
In mice, EP4 is the most abundantly expressed prostaglandin receptor within the heart 
(Xiao et al., 2004).  Previous reports have demonstrated expression of all four  
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Fig. 9. Expression of prostaglandin E2 receptors by PCR.  Cardiac progenitor cell clones 
were examined by PCR to determine whether they expressed prostaglandin E2 receptors.  
PCR products were run on a gel.  Transcripts for EP1 (size = 323bp) EP2 (size = 327bp) 
and EP4 (size = 464bp) were expressed on cardiac progenitor cell clones.  EP3 (size = 384 
bp) transcript expression was not found.   
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prostaglandin E2 receptors on other human stem cell types such as mesenchymal (Jang et 
al., 2012) and hematopoietic stem cells (Hoggatt et al., 2009), however whether resident 
human cardiac progenitors express receptors for prostaglandin E2 is unknown.  We 
therefore measured transcripts for the four prostaglandin receptors by PCR.  Isl-1+ c-kit+ 
cardiac progenitors expressed transcripts for EP1 (product size 323bp), EP2 (product size 
327bp), and EP4 (product size 464bp).  EP3 (product size 384bp), however, was not 
expressed in any of the CPC clones tested (Fig. 9).     This suggests that the response of 
human CPCs to prostaglandin E2 is possibly mediated through signaling in one or more 
of the prostaglandin receptors including EP1, EP2, and EP4, but not likely EP3. 
Enhanced migration in cardiac progenitors after prostaglandin E2 treatment could 
involve signaling in the PI3K-AKT pathway (Guo et al., 2014).   Prostaglandin E2 
treatment (in cancer cells, tendon stem cells, and dendritic cells) can increase PI3K-AKT  
signaling as evidenced by increased levels of phosphorylated AKT (George, Sturmoski, 
Anant, & Houchen, 2007; J. Liu, Chen, Tao, & Tang, 2013; Vassiliou, Sharma, Jing, 
Sheibanie, & Ganea, 2004).  In this study, we quantified the activation of the PI3K-AKT 
signaling pathway after prostaglandin E2 treatment by measuring the level of 
phosphorylated AKT by flow cytometry.  Surprisingly, treatment with 15 minutes of 
10µM PGE2, which can increase AKT phosphorylation in other cell types (Buchanan et 
al., 2006; Wang & Klein, 2007), decreased AKT phosphorylation levels in CPCs (3968 
MFU decrease, n=6, p=0.056, Fig. 10A&C).  This suggests that increased migration after 
PGE2 treatment in endogenous CPCs, is likely independent of PI3k-AKT signaling.  This 
decrease in phosphorylated AKT could hypothetically impact functions such as cell 
survival (Liou et al., 2007; Vassiliou et al., 2004).  
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Fig. 10. Changes in ERK and AKT phosphorylation after PGE2 treatment in starved 
medium.  Representative histograms displaying A) phosphorylated AKT and B) 
phosphorylated ERK protein expression levels by flow cytometry after 15 minutes of PGE2 
treatment.  C) Levels of phosphorylated AKT were decreased by PGE2 treatment but not 
significantly (n=6, p=0.056). D) Levels of phosphorylated ERK were significantly 
decreased after prostaglandin E2 treatment in cardiac progenitors (n=6, p=0.035).   
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At the present time, stem cell survival after transplantation has been reported to be 
relatively low to negligible on a long-term basis (K. U. Hong et al., 2014; Malliaras et al., 
2013).  Due to this fact, paracrine mechanisms (rather than direct differentiation), have 
been reported to account for the majority of the beneficial effects of cardiac stem cell 
transplantation (Chimenti et al., 2010; Kyung U Hong et al., 2014).  In other types of 
resident cardiac stem cells, the MAPK/ERK pathway regulates the secretion of beneficial 
paracrine factors (H. J. Lee et al., 2013).  When cardiac stem cells are in ERK-stimulating 
conditions, growth factors, such as VEGF, are secreted at elevated levels, whereas in 
ERK-inhibitory conditions, cells are more prone to cardiomyogenic differentiation (H. J. 
Lee et al., 2013).  The MAPK/ERK signaling pathway, if altered, can also affect cell 
proliferation, migration, stemness and secretory phenotype (Cho et al., 2012; H. J. Lee et 
al., 2013; Ryu et al., 2010; Xie et al., 2014).  We measured changes in the MAPK/ERK 
signaling pathway by quantifying the level of phosphorylated ERK (pERK) by flow 
cytometry.  After 15 minutes of exposure to 10µM PGE2, the level of pERK declined 
significantly (19,406 MFU decrease, n=6, p=0.035, Fig. 10B&D).  This same time frame 
increases ERK phosphorylation in other cell types (Krysan et al., 2005; Rao et al., 2007). 
Under “ERK-inhibitory” conditions (H. J. Lee et al., 2013) we would expect 
decreased growth factor expression.  After prostaglandin E2 exposure we used RT-PCR 
to quantify the expression of paracrine factors in Isl-1+c-kit+ cardiac progenitors.  These 
growth factors included hepatocyte growth factor (HGF), insulin-like growth factor 1 
(IGF-1), stromal cell-derived factor 1α (SDF-1α), and vascular endothelial growth factor 
A (VEGFA) which are all known to improve cell function and enhance cardiac  
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Fig. 11. Expression of growth factors in cardiac progenitor cell clones after PGE2 
treatment.  After 24 hours of 10µM PGE2, the expression of SDF-1, IGF1, and VEGFA 
were significantly downregulated in cardiac progenitor cell clones as shown by RT-PCR 
(n=3, run in triplicate, p<0.05). 
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regeneration after injury (Cheng et al., 2014; Hu et al., 2007; Linke et al., 2005; J. Tang 
et al., 2009).  As expected (based on ERK phosphorylation levels), 24 hours of 
prostaglandin E2 treatment significantly decreased the expression of transcripts for SDF-
1α, IGF1, and VEGFA (2.3 fold, 7.4 fold, and 9.5 fold respectively, p<0.0000001, Fig. 
11).  This decline in growth factor expression levels is a novel finding that is inconsistent 
with reports in other cell types (Jang et al., 2012; Junpeng Liu, Chen, Liu, & Tang, 2014; 
Peng et al., 2013; Zhao et al., 2012) and raises the possibility that prostaglandin E2 
treatment, in Isl-1+c-kit+ cardiac stem cells, may hinder their therapeutic efficacy after 
transplantation and consequently their regenerative capacity. 
In this study, prostaglandin E2 treatment lowered both the phosphorylation level 
of ERK and the expression of transcripts for SDF-1α, IGF-1, and VEGFA.  We therefore 
also measured the effect of PGE2 on the expression of cardiac specific transcripts, 
Troponin T and MLC2v.  After 24 hours of 10µM PGE2, we identified a trend (less than 
2-fold) towards increased expression levels of Troponin T and MLC2v that was not 
found to be significant when compared with untreated cells (Fig. 12, n=3, run in 
triplicate).  This suggests that 24 hours is not sufficient to significantly upregulate 
cardiac-specific transcripts associated with cardiomyogenic differentiation.   
 
Conclusions 
In this report, we evaluated the effect of prostaglandin E2 on Isl-1+c-kit+ cardiac 
progenitors derived from the human heart.  Although prostaglandin E2 is a crucial factor 
involved in cardiac regeneration (Degousee et al., 2008; Hsueh et al., 2014; Xiao et al., 
2004), at the current doses it is not a preferable pretreatment option for CPCs.  Resident  
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Fig. 12. Cardiac differentiation in CPCs after PGE2 treatment.  RT-PCR expression levels 
of cardiac-specific differentiation transcripts, cardiac troponin T (Trop T) and myosin light 
chain 2 (MLC2v), were not significantly altered after 24 hours of 10µM PGE2 treatment in 
cardiac progenitor cell clones (n=3, run in triplicate). 
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cardiac stem cells show enhanced cell migration after exposure to 10µM prostaglandin 
E2, however paracrine factor expression declines.  Likewise, the phosphorylation of ERK 
and AKT, key proteins involved in cell function and survival were decreased in CPCs 
after short-term prostaglandin E2 treatment. 
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CHAPTER FOUR 
CONCLUSIONS & FUTURE DIRECTIONS 
 
Summary 
 The purpose of this dissertation was to define key epigenetic, phenotypic, and 
functional changes that distinguish neonatal and adult cardiovascular progenitors.  In 
chapter 2, we determined that cardiac progenitors isolated from the adult human heart 
have a clear shift in microRNA expression profile with 41 significantly altered 
microRNAs.  These epigenetic differences may contribute to functional disparities 
evident between neonatal and adult cardiac progenitors including significantly decreased 
cell cycle progression and reduced SDF-1α-induced cell invasion in adult cardiac 
progenitors.  Interestingly, both neonatal and adult CPCs had similar cardiomyogenic 
differentiation ability as assessed by the expression of cardiac-specific transcripts during 
5-azacytidine induced cardiac differentiation by RT-PCR.  This change in cardiac stem 
cell functional ability is consistent with studies that have determined that neonatal CPCs 
have a higher regenerative ability in vivo when compared with adult CPCs (Simpson et 
al., 2012).  We also distinguished a subpopulation of cardiac progenitors that express 
SSEA4, which have superior ability to invade in response to growth factor simulation. 
In chapter 3, our goal was to investigate a novel strategy to improve cardiac 
progenitor cell function that could serve as a potential pre-treatment of cardiac 
progenitors prior to transplantation into the heart after injury.  To this end, we assessed 
the effect of a combination of hypoxia and prostaglandin E2 on CPC function.  The 
treatment of CPC with hypoxia for 48 hours followed by an acclimatization period of 
normal culture conditions for 6 hours and then 6 hours of 10µM prostaglandin E2 did 
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increase ERK phosphorylation and migration when compared with untreated CPCs and 
CPCs treated with hypoxia alone.  However, treatment of CPCs with hypoxia (when 
administered alone) and the combination of hypoxia with prostaglandin E2 did not 
significantly alter cell cycle progression.  
 In this chapter we were also able to elucidate novel changes in CPC function in 
response to prostaglandin E2.  Although PGE2 treatment can benefit the heart in vivo, it 
may not uniformly improve cardiac stem cell function in vitro. We identified that CPCs 
expressed three of the four prostaglandin E2 receptors including EP1, EP2, and EP4 by 
PCR.  Twenty-four hours of 10µM PGE2 treatment significantly increased cell migration, 
but decreased the expression of paracrine factors that play important roles in myocardial 
regeneration.  Furthermore, short-term treatment with prostaglandin E2 decreased the 
phosphorylation of AKT and ERK, key signaling molecules involved in stem cell 
regenerative ability. 
 
Future Directions 
At the end of this work, we are left with several important questions that may 
serve as building blocks for future studies.  Our long-term goals are to define the 
mechanisms that contribute to cardiac stem cell-mediated myocardial regeneration and to 
optimize cardiac stem cell functional ability.    
The significant change in microRNA expression profile with age lends credence 
to the idea that the packaging and secretion of expressed microRNAs is also affected in 
aged CPCs.  MicroRNAs can act as paracrine factors by being packaged and secreted 
within small membrane vesicles of endocytic origin known as exosomes (Théry, 
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Zitvogel, & Amigorena, 2002).  However, it is unknown whether age influences the level 
of exosomes secreted by cardiac stem cells, and secondly whether age can alter the type 
and levels microRNAs packaged within exosomes.  To test this, we will first isolate 
exosomes and validate isolation by western blot marker CD63 as well as confirmation of 
relative size of isolated particles.  We will then be able to compare relative secretion 
levels of neonatal and adult cardiac progenitors, isolate microRNAs from exosomes 
(Moldovan, Batte, Wang, Wisler, & Piper, 2013), and determine the relative profile of 
microRNAs within exosomes derived from the neonatal and adult CPC conditioned 
medium.  Lastly, the relative ability of exosomes derived from neonatal and adult CPC to 
regulate gene expression and resistance to cell death in cardiomyocytes will be measured 
in vitro.  This will provide novel information regarding the shift in microRNA expression 
within exosomes with age in CPCs, and will allow us to correlate this shift in microRNA 
expression with functional differences in cardiomyocytes after exosome treatment in 
vitro.  
  Exosomes can act as critical agents in cardiac regeneration (Chen et al., 2013); 
transplantation of CDC-derived exosomes into injured mouse hearts recapitulates the 
regenerative and functional effects produced by CDC transplantation, and this effect is 
partially mediated by the microRNAs packaged within them (Ibrahim, Cheng, & Marban, 
2014).  In our work, and work from other laboratories, we have demonstrated the superior 
functional capacity of cardiac stem cells derived from the neonatal heart when compared 
with cardiac stem cells from the adult heart (Fuentes et al., 2013; Simpson et al., 2012).  
It is unknown, however, whether exosomes secreted from neonatal CPCs have a superior 
ability to ameliorate cardiac injury when compared with exosomes from adult CPCs.  To 
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evaluate this we could isolate exosomes from human neonatal and adult CPC conditioned 
medium and compare their therapeutic efficacy in a mouse model of myocardial 
infarction by intramyocardial delivery of conditioned medium-derived exosomes.  Thirty 
days after exosome administration, relative infarct size and viable tissue as well as the 
level of apoptosis within the heart could be used to determine relative regenerative 
efficacy. 
The response of cardiovascular progenitors to prostaglandin E2 treatment outlined 
in chapter 3 in light of the overwhelming evidence of benefits of prostaglandin E2 in 
cardiac injury (Hsueh, Wu, Yu, Wu, & Hsieh, 2014) leaves the question as to the 
mechanisms responsible for this disparity in effect.  It is known, in other types of stem 
cells, that PGE2 can have a biphasic effect with opposing responses at low and high doses 
(Kleiveland, Kassem, & Lea, 2008; Zhang & Wang, 2014).  Although, in our study, we 
did not see uniformly beneficial effects of prostaglandin E2 treatment, this could be due 
to dose, duration of treatment, and receptor levels.  There are four known receptors for 
prostaglandin E2 including EP1, EP2, EP3, and EP4.  Interestingly, PGE2 treatment can 
regulate the abundance of its own receptors (Jang et al., 2012).  Therefore future work 
could contrast the effect of low and high doses of prostaglandin E2 on cardiac progenitor 
cell function, and evaluate the receptors responsible for functional changes. 
After low and high doses of PGE2 we would assess the relative level of EP1-4 
receptors and correlate receptor levels to changes in functional parameters such as cell 
stemness, cell differentiation, as well as cell cycle progression, migration, and growth 
factor expression.  To further define the mechanism by which differing doses of PGE2 
mediates its effect on CPCs, we would use specific receptor blockers (Sugimoto & 
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Narumiya, 2007) for the EP receptors to assess which receptors are responsible for select 
cardiac progenitor cell responses to PGE2.  We would also assess downstream signaling 
transcripts associated with a given receptor to pinpoint the signaling responsible for the 
differing effects.  This approach would further define the mechanism by which dose and 
PGE2 receptor levels govern CPC response to PGE2 treatment. 
 
Conclusions 
At the conclusion of this work, we have a better understanding of some of the 
various mechanisms underlying superior neonatal regenerative ability and have identified 
novel targets for improving adult CPC function.  We have established that, with age, 
there is a shift in human CPC microRNA expression profile which correlates with 
functional differences between neonatal and adult CPCs in vitro.  We have also evaluated 
a novel combination of prostaglandin E2 and hypoxia and identified changes in CPC 
function in response to PGE2 treatment including significantly reduced growth factor 
expression, and reduced signaling that may hinder CPC therapeutic efficacy.   
The work outlined in this dissertation provides important advancements to the 
field of cardiac stem cell mediated regeneration, and provides insight into novel 
therapeutic targets and strategies to help repair the damaged heart. 
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Supplementary Figure 3 Changes in ERK phosphorylation after time course of cardiac 
progenitor cell exposure to 1% O2. 
 
 
 
 
 
Cardiac progenitors were exposed to 6 hours (n=7), 24 hours (n=3), and 48 hours (n=8) of 
hypoxia (1% O2) and ERK phosphorylation was measured by flow cytometry.  The mean 
fluorescence shift above secondary antibody alone is shown above.  Levels of ERK 
phosphorylation in response to hypoxia were only significantly elevated in cardiac 
progenitors after 48 hours of hypoxia (3423 vs 2683 MFU, p=0.03). 
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Supplementary Figure 4 ERK phosphorylation after combination of Prostaglandin E2 
and hypoxia treatment.   
 
 
 
 
Cardiac progenitors were treated with 48 hours of 1% oxygen then 6 hours of normal 
growth medium (GM) followed by 6 hours of 10µM PGE2. Flow cytometry was used to 
measure ERK phosphorylation, mean fluorescence shift above secondary alone is shown 
above.  ERK phosphorylation was increased with a combination of hypoxia and 
prostaglandin E2 treatment (n=4, p=0.15) when compared with untreated cells.  
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Supplementary Figure 5 Cell cycle progression after hypoxia or combination hypoxia 
and prostaglandin E2 treatment.   
 
 
 
 
 
Cell cycle progression after hypoxia or combination hypoxia and prostaglandin E2 
treatment.  Cardiac progenitors were incubated for 48 hours with hypoxia (1% Oxygen) or 
a combination of hypoxia and prostaglandin E2.  For the combination treatment, cardiac 
progenitors were treated with 48 hours of hypoxia (followed by 6 hours of normal culture 
conditions for acclimatization) then 6 hours 10µM prostaglandin E2 in normal growth 
medium. Cell cycle progression was not significantly altered by treatment with hypoxia 
alone (n=4), or a combination of hypoxia and PGE2 (n=4) when compared with untreated 
cells. 
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Supplementary Figure 6 Migration in cardiovascular progenitors after consecutive 
treatment with hypoxia and PGE2.    
 
 
 
Cardiac progenitor cell clones were cultured in a hypoxia chamber for 48 hours, then 6 
hours of normal culture conditions, followed by 6 hours of 10µM PGE2. Migration was 
assessed using a transwell migration assay.  Combination treatment increased migration 
but not significantly (9083 vs 5455 cells, p=0.07). 
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Supplementary Table 1 Cell surface phenotype of neonatal and adult CPCs as 
identified by flow cytometry. 
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Supplementary Table 2 Antibodies used to characterize cell surface markers 
expressed on neonatal and adult CPC clones. 
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Supplementary Table 3 Relative expression of significantly altered microRNAs 
in neonatal and adult cardiovascular progenitors. 
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Supplementary Table 4 Pathway analysis associated with microRNAs that were 
differentially regulated when comparing neonatal and adult CPCs 
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Supplementary Table 5 Relative expression of significantly altered microRNAs 
in SSEA-4+ neonatal and adult cardiovascular progenitors 
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Supplementary Table 6 Primers used to detect gene expression by PCR  
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Supplementary Table 7 Primers used for Real-time PCR 
 
 
 
